Anti-CD94 antibodies and chimeric antigen receptors and methods of use thereof

By developing antibodies and chimeric antigen receptors that can bind CD94, the problem that CAR-T cell therapy is difficult to target NK/T cell lymphoproliferative diseases is solved, and safe and effective attacks on CD94-expressing cells are achieved, and the therapeutic effect is improved .

CN119095615APending Publication Date: 2024-12-06BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380021673.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-11
Filing Date
2023-01-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing CAR-T cell therapies are difficult to identify suitable antigens, and targeting natural killer (NK) cells and T cell lymphoproliferative disorders is challenging, especially because CD94 is expressed in normal tissues, resulting in difficult control of therapeutic efficacy and safety. .

Method used

Develop antibodies or antigen-binding fragments thereof that bind CD94, including specific anti-CD94 antibodies and chimeric antigen receptors (CARs), through which these antibodies or CAR-T cells target CD94-expressing cells to achieve NK/T cell lymph Treatment of proliferative disorders.

Benefits of technology

It provides a safe and effective targeting strategy that specifically attacks CD94-expressing NK/T cells, improves the therapeutic effect of CAR-T cell therapy, and reduces damage to normal tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004991520680000271
    Figure BDA0004991520680000271
  • Figure BDA0004991520680000272
    Figure BDA0004991520680000272
  • Figure BDA0004991520680000281
    Figure BDA0004991520680000281
Patent Text Reader

Abstract

According to various aspects of the present disclosure, the disclosure relates to an antibody, or an antigen-binding fragment thereof, capable of binding CD94, a chimeric antigen receptor capable of binding CD94, and an engineered T cell containing a chimeric antigen receptor capable of binding CD94.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 298,423, filed on January 11, 2022, which is hereby incorporated by reference in its entirety.

[0003] Citations of Sequence Listings Submitted Electronically via EFS-WEB

[0004] The contents of the electronically submitted sequence listing filed with this application (name: 4443_010PC01_Seqlisting_ST26.xml, size: 73,637 bytes; and creation date: January 5, 2023) are incorporated herein by reference in their entirety. Technical Field

[0005] The present disclosure generally relates to the fields of immunology and cancer treatment. For example, the present disclosure provides anti-CD94 antibodies, anti-CD94 chimeric antigen receptors and anti-CD94 CAR-T cells, and methods of making and using the same. Background Art

[0006] Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy against B-cell leukemias and lymphomas. However, targeting natural killer (NK) cells and T-cell lymphoproliferative disorders has been challenging due to the difficulty in identifying antigens suitable for CAR-T cell therapy.

[0007] CD94 is a C-type lectin receptor expressed on a subset (<5%) of NK cells and CD8+ T cells in normal tissues. It can function as either a stimulatory or inhibitory receptor when it forms a heterodimer with NKG2C or NKG2A, respectively. Studies of patients with primary immunodeficiency, in which NK cell deficiency is the primary immunodeficiency, have shown that they are primarily at risk for recurrent herpesvirus infections, which can be managed with a combination of vaccination, prophylaxis, and / or therapeutic strategies. Collectively, these reports suggest that CD94 may be a safe and effective target for CAR T-cell therapy for NK / T-cell lymphoproliferative disorders that express CD94.

[0008] There is a need to develop antibodies and CAR-T cells, for example, for the treatment of natural killer cells and T-cell lymphoproliferative disorders. Summary of the invention

[0009] The present disclosure provides antibodies or antigen-binding fragments thereof (e.g., anti-CD94 specific antibodies) that can bind to CD94. In some aspects, the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence YTS, SEQ ID NO: 23 or SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0010] In some aspects, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL). In some aspects, VH comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 1, and VL comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 2.

[0011] In some aspects, the antibody or antigen-binding fragment thereof comprises: i) CDR H1, CDR H2, and CDR H3 comprising the CDR H1, CDR H2, and CDR H3 amino acid sequences of SEQ ID NO: 1; and ii) CDR L1, CDR L2, and CDR L3 comprising the CDR L1, CDR L2, and CDR L3 amino acid sequences of SEQ ID NO: 2.

[0012] In some aspects, the CDRs are Kabat-defined CDRs, Chothia-defined CDRs, AbM-defined CDRs, or IMGT-defined CDRs.

[0013] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:1.

[0014] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:1.

[0015] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

[0016] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:1.

[0017] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO:1.

[0018] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:2.

[0019] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:2.

[0020] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2.

[0021] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:2.

[0022] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO:2.

[0023] In some aspects, the antibody or antigen-binding fragment thereof is human, humanized, or chimeric.

[0024] In some aspects, the antibody or antigen-binding fragment thereof is an IgG antibody.

[0025] In some aspects, the IgG antibody is an IgG1 antibody or an IgG4 antibody.

[0026] In some aspects, the antibody is an antigen-binding fragment of an antibody.

[0027] In some aspects, the fragment is selected from the group consisting of Fab, F(ab')2, Fv, scFv, scFv-Fc, dsFv and a single domain molecule.

[0028] In some aspects, the fragment is a scFv.

[0029] In some aspects, the fragment is a Fab.

[0030] In some aspects, the fragment is an intrabody.

[0031] In some aspects, the antigen binding fragment lacks an Fc region.

[0032] In some aspects, the antibody or antigen-binding fragment comprises VH and VL on the same polypeptide chain.

[0033] In some aspects, the VH and VL are connected by a linker.

[0034] In some aspects, the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.

[0035] In some aspects, the antibody or antigen-binding fragment thereof is a bispecific antibody.

[0036] In some aspects, disclosed herein is a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising an antigen binding domain capable of binding to CD94; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain. In some aspects, the antigen binding domain comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0037] In some aspects, the chimeric antigen receptor comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:2.

[0038] In some aspects, the antigen binding domain is a scFv.

[0039] In some aspects, the costimulatory domain comprises a 4-1BB costimulatory domain, a CD28 costimulatory domain, or an OX40 costimulatory domain.

[0040] In some aspects, the hinge, the transmembrane domain, or both are from a CD8 alpha polypeptide.

[0041] In some aspects, the signaling domain comprises a CD3 zeta signaling domain.

[0042] In some aspects, disclosed herein is an engineered human T cell comprising a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising a scFv domain capable of binding to CD94, wherein the scFv domain comprises VL and VH; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain. In some aspects, VH comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, and a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21. In some aspects, VL comprises: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO:23 or SEQ ID NO:24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:8.

[0043] In some aspects, the engineered human T cells comprise a chimeric antigen receptor (CAR) comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 9, 56 or 57.

[0044] In some aspects, disclosed herein are isolated polynucleotides comprising a nucleic acid molecule encoding the VH or heavy chain of any of the antibodies or antigen-binding fragments thereof disclosed herein.

[0045] In some aspects, the isolated polynucleotide further comprises a nucleic acid molecule encoding any VL or light chain of the antibodies or antigen-binding fragments thereof disclosed herein.

[0046] In some aspects, disclosed herein are isolated polynucleotides comprising a nucleic acid molecule encoding any of the VL or light chains of the antibodies or antigen-binding fragments thereof disclosed herein.

[0047] In some aspects, disclosed herein are isolated polynucleotides comprising a nucleic acid molecule encoding any of the chimeric antigen receptors disclosed herein.

[0048] Disclosed herein, in some aspects, are isolated vectors comprising any of the polynucleotides disclosed herein.

[0049] In some aspects, disclosed herein are host cells comprising any polynucleotide disclosed herein or any vector disclosed herein.

[0050] In some aspects, the host cell is selected from the group consisting of CHO, HEK-293T, HeLa and BHK cells, optionally wherein the CHO cell is a CHO-K1SP cell.

[0051] In some aspects, disclosed herein is a method of producing an antibody or antigen-binding fragment thereof that can bind to CD94, the method comprising: (a) culturing any host cell disclosed herein in cell culture under conditions that allow expression of the antibody or antigen-binding fragment thereof; and (b) recovering the antibody or antigen-binding fragment thereof from the cell culture.

[0052] In some aspects, disclosed herein are antibodies or antigen-binding fragments thereof obtainable by any of the production methods disclosed herein.

[0053] In some aspects, disclosed herein is a pharmaceutical composition comprising any antibody or antigen-binding fragment thereof disclosed herein, any chimeric antigen receptor disclosed herein, any engineered T cell disclosed herein, or any vector disclosed herein. In some aspects, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0054] In some aspects, disclosed herein are methods of treating cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of any antibody or antigen-binding fragment thereof disclosed herein, any chimeric antigen receptor disclosed herein, any engineered T cell disclosed herein, or any pharmaceutical composition disclosed herein.

[0055] In some aspects, the cancer is a leukemia. In some aspects, the cancer is a cancer that expresses CD94.

[0056] In some aspects, the leukemia is T-cell leukemia, T-cell large granular leukemia, natural killer cell large granular leukemia, or natural killer cell leukemia.

[0057] In some aspects, the cancer is lymphoma.

[0058] In some aspects, the lymphoma is T-cell lymphoma, extranodal natural killer / T-cell lymphoma, hepatosplenic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, or anaplastic large cell lymphoma.

[0059] In some aspects, described herein are methods of treating or preventing transplant rejection of a transplanted patient, the methods comprising administering to the individual a therapeutically effective amount of any antibody or antigen-binding fragment thereof described herein, any chimeric antigen receptor described herein, any engineered T cell described herein, or any pharmaceutical composition described herein.

[0060] In some aspects, the transplant is an allogeneic transplant.

[0061] In some aspects, the transplant is an organ transplant.

[0062] In some aspects, the transplant is a hematopoietic cell transplant.

[0063] In some aspects, the transplant is induced pluripotent cell therapy.

[0064] In some aspects, described herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any antibody or antigen-binding fragment thereof described herein, any chimeric antigen receptor described herein, any engineered T cell disclosed herein, or any pharmaceutical composition disclosed herein.

[0065] In some aspects, the immune response is enhanced.

[0066] In some aspects, immune response is mediated by natural killer cells and / or T cells. In some aspects, the immune response of natural killer cells and / or T cells mediate autoimmune diseases. In some aspects, autoimmune diseases are systemic autoimmune diseases. In some aspects, systemic autoimmune diseases are systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis (RA), multiple sclerosis, type 1 diabetes (T1DM) or autoimmune liver disease (ALD). BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1A Shown is the expression of CD94 mRNA relative to β-actin mRNA in the natural killer (NK) cell lymphoma cell line NK-92 and normal human tissues.

[0068] Figure 1B Shown is the expression of CD94 mRNA in 79 normal human tissues and lymphoma subtypes measured by BioGPS's high-density oligonucleotide array.

[0069] Figure 2Shown is flow cytometric analysis indicating the generation of CD94-L cells by measuring positive staining for CD94 (x-axis).

[0070] Figures 3A-3C The specificity of a purified anti-CD94 monoclonal antibody ("UT-CD94") produced by hybridoma technology is shown. Figure 3A Shown is the staining of CD94-L cells (CD94-L) and L cells (L) by UT-CD94 monoclonal antibody conjugated to AF647. Figure 3B Shown is the staining of CD56+NK cells (NK cells), CD3+T cells (T cells), CD19+B cells (B cells), and CD14+ monocytes (monocytes) from normal donor peripheral blood mononuclear cells by UT-CD94 monoclonal antibody conjugated to AF647. Figure 3C Shown is the staining of NK lymphoma or leukemia cell lines (NK-92, NKL, and KHYG-1) and B cell lymphoma cell lines (SP53, Daudi, and Jeko-1) by UT-CD94 monoclonal antibody conjugated to AF647.

[0071] Figure 4A An exemplary design of an anti-CD94 chimeric antigen receptor ("UT-CD94 CAR") is shown. The UT-CD94 CAR includes (i) a CD94 scFv comprising a VL and VH domain, (ii) a CD8α hinge domain, (iii) a CD8α transmembrane domain, (iv) a 4-1BB co-stimulatory domain, and (v) a CD3ζ signaling domain.

[0072] Figure 4B Shown is the expression of UT-CD94 CAR 72 hours after lentiviral transduction as determined by staining with His-tagged CD94 extracellular domain (ECD) protein and AF647-conjugated anti-His antibody. Flow cytometric analysis shows positive staining for UT-CD94 CAR on the x-axis.

[0073] Figures 5A-5F The cytotoxicity of anti-CD94 CAR-T cells ("UT-CD94 CAR-T cells") is shown. Figure 5A-5B Figure 3 shows the expression of the CD94-positive NK cell line NKL (NKL) after co-culture with UT-CD94 CAR-T cells (CD94CAR-T), co-culture with untransduced T cells (control T), or no co-culture (tumor only). Figure 5A ) or NK-92( Figure 5B ) Percent lysis at effector:target ratios of 8:1, 4:1, and 1:1. Figure 5C-E shows the CD94-positive NK cell line NKL ( Figure 5C ), CD94 positive NK cell line NK-92 ( Figure 5D ) or the B-cell lymphoma cell line SP53 ( Figure 5E ) The corresponding lysis percentage during 4 days. Fig. 5F Shown are the percentages of dead target cells in L cells, human CD94-transfected L cells, the B-cell lymphoma cell line SP53, and the NK92 cell line when cultured alone or in combination with untransduced T cells, anti-CD94 CAR-T cells, or anti-CD19 CAR-T cells at an effector:target ratio of 6:1 for 24 hours.

[0074] Figure 6 Shown are flow cytometric analyses measuring the effects of chimeric anti-CD94 antibodies ("cUT-CD94") or isotype antibodies on HLA-E tetramer staining (measured by median fluorescence intensity).

[0075] Figure 7 Shown is flow cytometric analysis measuring CD137+ NK cells after incubation with HLA-E expressing SP-53 mantle cell lymphoma cells and treatment with mouse anti-human CD94 antibody (UT-CD94 / mCD94 and DX22 from Biolegend), cUT-CD94 antibody (cCD94), and relevant isotype controls (mIgG1 and hIgG1 from Biolegend).

[0076] Figure 8 Shown is flow cytometric analysis measuring CD107a+ NK cells after incubation with HLA-E expressing SP-53 mantle cell lymphoma cells and treatment with mouse anti-human CD94 antibody (UT-CD94 / mCD94 and DX22 from Biolegend), cUT-CD94 antibody (cCD94) and relevant isotype controls (mIgG1 and hIgG1 from Biolegend).

[0077] Figures 9A-9G scRNAseq analysis showing CD94 (KLRD1) mRNA expression. Overview of CD94 mRNA expression based on 25 normal human tissues ( Fig.9A ), single cell types from all 25 tissues ( Fig. 9B ),heart( Fig. 9C ),lung( Fig.9D ),liver( Fig.9E ) and kidney( Fig.9F). In addition, CD94 mRNA expression in 29 immune cell types from peripheral blood of normal donors was analyzed ( Figure 9G ). nTPM – normalized transcripts per million. Source: Human Protein Atlas.

[0078] Figures 10A-10C Shown in normal donor tissue array ( Fig. 10A )、Normal tonsils( Fig. 10B ) and tumor biopsies from subjects with NK / T-cell lymphoma ( Fig. 10C ) Immunohistochemical determination of CD94 expression in .

[0079] Fig.11 Binding of anti-CD94 antibodies in wild-type and CD94 knockout NK cell leukemia cell lines is shown. Binding specificity of anti-CD94 antibodies was assessed by flow cytometry relative to wild-type KHYG-1 and NK92 cell lines and their isogenic cell lines with CD94 knockout (KO).

[0080] Figures 12A-12E Exemplary CD94-targeted CAR constructs and their in vitro cytotoxic activity are shown. Fig. 12A Three different designs of CD94-targeting CARs are shown. Fig. 12B Flow cytometric evaluation of CD94-targeted CAR lentiviral transduction into normal donor T cells is shown. Figures 12C-12E The percentage of cells undergoing lysis or growth as monitored by continuous imaging using the Incucyte Live Cell Analysis System is shown. Fig. 12C 、KHYG-1- Fig.12D and NK92- Fig.12E ). Tumor cells were then cultured in the presence or absence of CD94-targeted CAR T cells or untransduced T cells at an effector:target ratio of 0.5:1.

[0081] Figures 13A-13C Expression of CD94 in hepatosplenic T-cell lymphoma and cytotoxicity of anti-CD94 against PDX tumor cells are shown. Fig.13A The results show that intravenous injection of hepatosplenic T-cell lymphoma (TCL) PDX cells (1x10 6 Photographs of liver and spleen at necropsy of NSG mice with 4 tumor cells / mouse. Fig. 13BShown is the expression of CD3 (hCD3), CD94 (hCD94) and CD45 (hCD45) in liver, spleen, bone marrow and blood measured by flow cytometry between hCD3+hCD45+ cells and hCD3-hCD45- cells. NSG mice not injected with tumors were used as controls. Fig. 13C Survival rates are shown for 5 different groups of mice: 1) tumor only, 2) untransduced T cells, 3) mice administered 10x10 6 mice with anti-CD94 targeted CAR+T cells (CD94 / CD28), 4) administered 10x10 6 mice with anti-CD94 targeted CAR+T cells (CD94 / 4-1BB), 5) administered 10x10 6 Mice with anti-CD94 targeted CAR+T cells (CD94 / OX40). The anti-tumor effect of CAR T cells was evaluated by monitoring the survival rate of mice. The log-rank test was used to evaluate the survival difference between the treatment groups. DETAILED DESCRIPTION

[0082] Certain aspects of the present disclosure relate to anti-CD94 antibodies, anti-CD94 chimeric antigen receptors and anti-CD94 CAR-T cells, and methods of making and using the same. In some aspects, disclosed herein are antibodies or antigen-binding fragments thereof that are capable of binding to CD94. In some aspects, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), comprising: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:20, and a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:21; and a light chain variable region (VL), comprising: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO:23 or SEQ ID NO:24, and a CDRL3 comprising the amino acid sequence shown in SEQ ID NO:8. In some aspects, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and a light chain variable region (VL) comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment thereof comprises an anti-CD94 scFv comprising a VL and a VH domain. In some aspects, disclosed herein are chimeric antigen receptors (CARs) or CAR T cells comprising an anti-CD94 antibody or antigen-binding fragment thereof disclosed herein (e.g., an anti-CD94 scFv).

[0083] I. Definitions

[0084] Unless otherwise defined, all technical terms and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. In the event of a conflict, the present application (including definitions) shall prevail. In addition, unless the context otherwise requires, singular terms shall include plural terms and plural terms shall include singular terms. All publications, patents and other references mentioned herein are incorporated herein by reference in their entirety for all purposes, as if each individual publication or patent application is explicitly and individually indicated to be incorporated by reference.

[0085] Although methods and materials similar or equivalent to those disclosed herein may be used in the practice or testing of the present disclosure, suitable methods and materials are disclosed below. Materials, methods and embodiments are illustrative only and are not intended to be limiting. Other features and advantages of the present disclosure will be apparent from the specific embodiments and claims.

[0086] To further define the present disclosure, the following terms and definitions are provided.

[0087] Unless the context clearly dictates otherwise, the singular forms "a / an" and "the" include plural referents. The terms "a / an" and the terms "one or more" and "at least one" may be used interchangeably herein. In certain aspects, the terms "a / an" refer to "single". In other aspects, the terms "a / an" include "two or more" or "multiple".

[0088] The term "about" is used herein to mean approximately, roughly, about, or around. When the term "about" is used in conjunction with a numerical range, it modifies the range by extending the boundaries above and below the numerical values. In general, the term "about" is used herein to modify a numerical value by a variation of 10% above and below (increases or decreases) above and below the value.

[0089] Throughout the present disclosure, various aspects of the present disclosure are presented in the form of ranges. Numerical ranges include numbers that limit the range. When enumerating the range of values, it should be understood that each intermediate integer value and each fraction thereof between the upper and lower limits of the range are also specifically disclosed, as well as each subrange between such values. The upper and lower limits of any range can be independently included in the range or excluded from the range, and each range including any one limit, both limits do not include or include both limits is also included in the present disclosure. Therefore, the ranges listed herein should be understood as the shorthand form of all values ​​in the range, including the endpoints listed. For example, a range of 1 to 10 is understood to include any numerical value, numerical combination or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

[0090] Where values ​​are explicitly listed, it is understood that values ​​of quantities or amounts that are approximately the same as the listed values ​​are also within the scope of the present disclosure. Where combinations are disclosed, each subcombination of the elements of the combination is also specifically disclosed and is within the scope of the present disclosure. Conversely, where different elements or groups of elements are disclosed separately, combinations thereof are also disclosed. Where any element of the present disclosure is disclosed as having multiple alternatives, embodiments of the present disclosure in which each alternative is excluded, either individually or in combination with other alternatives, are also hereby disclosed; more than one element of the present disclosure may have such exclusions, and all combinations of elements having such exclusions are hereby disclosed.

[0091] When used herein, the term "and / or" should be considered to specifically disclose each of the two specified features or components, with or without the other. Thus, the term "and / or" used herein in phrases such as "A and / or B" is meant to include: "A and B"; "A or B"; "A" (alone); and "B" (alone). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0092] As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, preparations and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0093] The term "excipient" refers to any substance that is not a therapeutic agent itself, which can be used in a composition to deliver an active therapeutic agent to a subject or to be combined with an active therapeutic agent (e.g., to produce a pharmaceutical composition) to improve its handling or storage characteristics or to allow or facilitate the formation of a composition dosage unit (e.g., to form a hydrogel, which can then be optionally incorporated into a patch). Excipients include, but are not limited to, solvents, penetration enhancers, wetting agents, antioxidants, lubricants, emollients, substances added to improve the appearance or texture of the composition, and substances for forming hydrogels. According to the present disclosure, any such excipient can be used in any dosage form. The aforementioned excipient categories are not exhaustive, but merely illustrative, because those of ordinary skill in the art will recognize that other types and combinations of excipients can be used to achieve the desired goal of drug delivery. Excipients can be inert substances, inactive substances, and / or non-pharmaceutically active substances. Excipients can be used for a variety of purposes. Those skilled in the art can select one or more excipients by routine experiments relative to specific desired properties without any excessive burden. The amount of each excipient used can vary within the conventional range of the art. Techniques and excipients that can be used to formulate dosage forms are described in Handbook of Pharmaceutical Excipients, 6th edition, Rowe et al., eds., American Pharmaceuticals Association and the Pharmaceutical Press, publications department of the Royal Pharmaceutical Society of Great Britain (2009); and Remington: the Science and Practice of Pharmacy, 21st edition, Gennaro, Ed., Lippincott Williams & Wilkins (2005).

[0094] As used herein, the term "effective amount" or "pharmaceutically effective amount" or "therapeutically effective amount" refers to the amount or quantity of a drug or pharmaceutically active substance sufficient to elicit the required or desired therapeutic response, or in other words, an amount sufficient to elicit a significant biological response when administered to a patient.

[0095] As used herein, the terms "treating" or "treatment" refer to the administration of a composition to a subject for therapeutic purposes.

[0096] The term "antibody" means an immunoglobulin molecule that recognizes and specifically binds to a target through an antigen recognition site in at least one immunoglobulin molecule variable region, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing. As used herein, the term "antibody" encompasses complete polyclonal antibodies, complete monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising antibodies, and any other modified immunoglobulin molecules, as long as the antibody exhibits desired biological activity. The antibody may belong to any of the five main immunoglobulin classes: IgA, IgD, IgE, IgG, and IgM, or its subclass (isotype) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), and is referred to as α, δ, ε, γ, and μ, respectively, based on the identity of their heavy chain constant domains. Different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations. Antibodies may be naked antibodies or conjugated with other molecules such as toxins, radioisotopes, etc.

[0097] The term "antibody fragment" refers to a portion of a complete antibody. An "antigen binding fragment," "antigen binding domain," or "antigen binding region" refers to a portion of a complete antibody that binds to an antigen. An antigen binding fragment may contain the antigen recognition site of a complete antibody (e.g., a complementary determining region (CDR) sufficient to bind to an antigen). Examples of antigen binding fragments of antibodies include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, and single-chain antibodies. Antigen binding fragments of antibodies may be derived from any animal species, such as rodents (e.g., mice, rats, or hamsters) and humans, or may be artificially produced.

[0098] As used herein, the terms "variable region" or "variable domain" are used interchangeably and are common in the art. Variable region generally refers to a part of an antibody, generally a part of a light chain or a heavy chain, generally refers to about 110 to 120 amino acids or 110 to 125 amino acids at the amino terminal in a mature heavy chain and about 90 to 115 amino acids in a mature light chain, which have differences in sequence between antibodies and are used for the binding and specificity of a particular antibody for its specific antigen. The variation of the sequence is concentrated in the region called the complementary determining region (CDR), while the more highly conserved region in the variable domain is called the framework region (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that the CDR of light and heavy chains is primarily responsible for the interaction and specificity of the antibody with the antigen.

[0099] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody or antigen-binding fragment thereof.

[0100] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody or antigen-binding fragment thereof.

[0101] The hypervariable regions in each chain are held together in close proximity by the FRs and contribute to the formation of the antigen binding site of the antibody together with the hypervariable regions from the other chain (see Kabat et al., Sequences of Proteins of Immunological Interest, 1992). The term "hypervariable region" as used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR", which has the highest sequence variability and / or is involved in antigen recognition. There are many CDR definitions in use and are covered herein. The Kabat definition is based on sequence variability and is the most commonly used definition (Kabat EA et al., supra). Chothia refers to the position of the structural loop (Chothia C & LeskAM (1987) J.Mol.Biol.196:901-917). The AbM definition is a compromise between the Kabat and Chothia definitions and is used by Oxford Molecular's AbM antibody modeling software (Martin AC R et al., (1989) Proc. Natl Acad. Sci. USA, 86:9268-72; Martin AC R et al., (1991) Methods Enzymol. 203:121-153; Pedersen JT et al., (1992) Immunomethods, 1:126-136; Rees AR et al., (1996) In Sternberg MJE (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172). The contact definition was introduced more recently (Maccallum RM et al., (1996) J. Mol. Biol. 262:732-745) and is based on an analysis of complex structures available in the Protein Data Bank. International Immunogenetics Information System (http: / / www.imgt.org) The definition of CDRs is based on the IMGT numbering of all immunoglobulins and T-cell receptor V-REGIONs from all species ( the international ImMunoGeneTicsinformation Lefranc MP et al., (1991) Nucleic Acids Res. 27(1):209-12; Ruiz M et al., (2000) Nucleic Acids Res. 28(1):219-21; Lefranc MP (2001) Nucleic Acids Res. 29(1):207-9; Lefranc MP (2003) Nucleic Acids Res. 31(1):307-10; Lefranc MP et al., (2005) Dev. Comp. Immunol. 29(3):185-203; Kaas Q et al., (2007) Briefings in Functional Genomics & Proteomics, 6(4):253-64).

[0102] In some aspects, the complementarity determining regions (CDRs) disclosed herein are according to In some aspects, CDR is defined according to Chothia. In some aspects, CDR is defined according to Kabat. For example, for light chain, the variable domain residues of each CDR can be (numbered according to Kabat EA et al. (supra)): LCDR1: 27-32, LCDR2: 50-52, LCDR3: 89-97. The "non-CDR region" in the VL region used herein comprises the following amino acid sequence: 1-26 (FR1), 33-49 (FR2), 53-88 (FR3) and 98-about 107 (FR4). For heavy chain, the variable domain residues of each CDR in the three CDRs can be HCDR1: 26-35, HCDR2: 51-57 and HCDR3: 93-102. As used herein, the "non-CDR region" of the VH region may include the following amino acid sequences: 1-25 (FR1), 36-50 (FR2), 58-92 (FR3), and 103 to about 113 (FR4).

[0103] The CDRs of the present disclosure may include "extended CDRs" based on the above definition, and may have the following variable domain residues: LCDR1: 24-36, LCDR2: 46-56, LCDR3: 89-97, HCDR1: 26-36, HCDR2: 47-65, HCDR3: 93-102. These extended CDRs are also numbered according to Kabat et al. (supra).

[0104] In some respects, alternative CDR sequences are provided for the same framework amino acid sequence of variable region. In some respects, alternative CDR sequences are generated using software programs. In some respects, different software can be used to generate alternative CDR sequences for the framework sequence of variable region, owing to using different software programs and causing different CDR sequences. In some respects, alternative CDR sequences can be used to improve the binding affinity of bispecific antibody to at least one antigen. In some respects, alternative CDR sequences are used for affinity optimization of one or two antigen binding sites of bispecific antibody according to the present invention. In some respects, alternative CDRs are defined according to Kabat, Chothia, Paratome, AbM, Contact and / or IMGT annotations. In some respects, CDR is defined according to more than one annotation.

[0105] The "non-extended CDR region" of the VL region may include the following amino acid sequence: 1-23 (FRI), 37-45 (FR2), 57-88 (FR3), and 98 to about 107 (FR4). The "non-extended CDR region" of the VH region may include the following amino acid sequence: 1-25 (FRI), 37-46 (FR2), 66-92 (FR3), and 103 to about 113 (FR4).

[0106] As used herein, the term "Fab region" refers to the VH and CHI domains of the heavy chain ("Fab heavy chain"), or the VL and CL domains of the light chain ("Fab light chain") of an immunoglobulin.

[0107] The term "scFv" or "single-chain antibody fragment" used herein refers to a single chain composed of the heavy chain variable region and the light chain variable region of an antibody linearly connected by a linker (e.g., a short peptide of 10-25 amino acids), which exhibits specific binding to an antigen.

[0108] As used herein, the terms "constant region" and "constant domain" are interchangeable and have common meanings in the art. The constant region is the portion of an antibody, e.g., the carboxyl terminal portion of a light chain and / or a heavy chain, which is not directly involved in binding the antibody to an antigen, but may exhibit various effector functions, such as interactions with Fc receptors. Relative to immunoglobulin variable domains, the constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence.

[0109] As used herein, the term "heavy chain" when used to refer to an antibody can refer to any of the different types, such as α (a), δ (d), ε (e), γ (g) and μ (m) based on the amino acid sequence of the constant domain, which produces IgA, IgD, IgE, IgG and IgM class antibodies, respectively, including subclasses of IgG, such as IgG1, IgG2, IgG3 and IgG4. The heavy chain amino acid sequences are well known in the art. In some aspects, the heavy chain is a human heavy chain.

[0110] As used herein, the term "light chain" when used to refer to an antibody can refer to any of the different types, such as kappa (K) or lambda (l) based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In some aspects, the light chain is a human light chain.

[0111] The term "chimeric" antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof in which the amino acid sequence is derived from two or more species. Typically, the variable regions of the light and heavy chains correspond to the variable regions of an antibody or antigen-binding fragment thereof with the desired specificity, affinity and capacity derived from one mammalian species (e.g., mouse, rat, rabbit, etc.), while the constant regions are homologous to sequences in an antibody or antigen-binding fragment thereof derived from another species (usually human) to avoid eliciting an immune response in this species.

[0112] The term "humanized" antibody or its antigen-binding fragment refers to a form of a non-human (e.g., mouse) antibody or antigen-binding fragment that is a specific immunoglobulin chain, chimeric immunoglobulin, or fragment thereof containing minimal non-human (e.g., mouse) sequences. Typically, a humanized antibody or its antigen-binding fragment is a human immunoglobulin in which residues from a complementary determining region (CDR) are replaced by residues from a CDR from a non-human species (e.g., mouse, rat, rabbit, hamster) with the desired specificity, affinity, and ability ("CDR grafting") (Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-327 (1988); Verhoeyen et al., Science 239: 1534-1536 (1988)). In some cases, the Fv framework region (FR) residues of a human immunoglobulin are replaced by corresponding residues from a non-human species antibody or fragment with the desired specificity, affinity, and ability. Humanized antibodies or their antigen-binding fragments can be further modified by replacing additional residues in the Fv framework region and / or in non-human CDR residues to improve and optimize the specificity, affinity and / or ability of the antibody or its antigen-binding fragment. In general, humanized antibodies or their antigen-binding fragments will comprise substantially all at least one, usually two or three variable domains, the variable domains comprising all or substantially all CDR regions corresponding to non-human immunoglobulins, and all or substantially all FR regions being those of human immunoglobulin consensus sequences. Humanized antibodies or their antigen-binding fragments may also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically at least a portion of an immunoglobulin constant region or domain (Fc) of a human immunoglobulin. Examples of methods for producing humanized antibodies are described in U.S. Pat. No. 5,225,539; Roguska et al., Proc. Natl. Acad. Sci., USA, 91(3):969-973 (1994) and Roguska et al., Protein Eng. 9(10):895-904 (1996). In some aspects, a "humanized antibody" is a resurfaced antibody.

[0113] The term "human" antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof having an amino acid sequence derived from a human immunoglobulin locus, wherein such antibody or antigen-binding fragment is made using any technique known in the art. This definition of human antibodies or antigen-binding fragments thereof includes complete or full-length antibodies and fragments thereof.

[0114] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or antigen-binding fragment thereof) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody or antigen-binding fragment thereof and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (KD). Affinity can be measured and / or represented in a variety of ways known in the art, including, but not limited to, the equilibrium dissociation constant (KD) and the equilibrium association constant (KA). KD is represented by k off / k on , and KA is calculated by k on / k off Calculate the quotient of k on refers to the association rate constant of, for example, an antibody or antigen-binding fragment thereof with an antigen, and k off Refers to, for example, the dissociation of an antibody or its antigen-binding fragment from an antigen. on and k off It can be determined by techniques known to those of ordinary skill in the art, such as or KinExA.

[0115] As used herein, "epitope" is a term in the art, referring to the local region of an antigen that an antibody or its Fab can specifically bind. An epitope can be, for example, the adjacent amino acids (linear or adjacent epitopes) of a polypeptide, or an epitope can be, for example, from two or more non-adjacent regions (conformational, non-linear, non-adjacent or non-adjacent epitopes) of one or more polypeptides together. In some aspects, the epitope that an antibody or its Fab is combined with can be determined by, for example, NMR spectroscopy, X-ray diffraction crystallography, ELISA determination, hydrogen / deuterium exchange and mass spectrometry coupling (for example, liquid chromatography electrospray mass spectrometry), array-based oligopeptide scanning determination and / or mutagenesis positioning (for example, site-directed mutagenesis positioning). For X-ray crystallography, crystallization can be accomplished using any method known in the art (e.g., Giege R et al., (1994) Acta Crystallogr DBiol Crystallogr 50(Pt 4):339-350; McPherson A (1990) Eur J Biochem 189:1-23; Chayen NE (1997) Structure 5:1269-1274; McPherson A (1976) J Biol Chem 251:6300-6303). Antigen crystals can be studied using well-known X-ray diffraction techniques, and can be improved using computer software such as X-PLOR (Yale University, 1992, published by Molecular Simulations, Inc.; See, e.g., Meth Enzymol (1985) Vol. 114 and 115, compiled by Wyckoff HW et al.; US 2004 / 0014194), and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49 (Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, compiled by Carter CW; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56 (Pt 10): 1316-1323). Mutagenesis location studies can be completed using any method known to those skilled in the art. For descriptions of mutagenesis techniques, including alanine scanning mutagenesis, see, eg, Champe M et al., (1995) J Biol Chem 270: 1388-1394 and Cunningham BC and Wells JA (1989) Science 244: 1081-1085.

[0116] An antibody is said to "competitively inhibit" binding of a reference antibody to a given epitope if the antibody preferentially binds to the given epitope or an overlapping epitope and blocks binding of the reference antibody to the epitope to some extent. Competitive inhibition can be determined by any method known in the art, e.g., a competition ELISA assay. An antibody can be said to competitively inhibit binding of the reference antibody to the given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.

[0117] An "isolated" polypeptide, antibody, polynucleotide, vector, cell or composition is a polypeptide, antibody, polynucleotide, vector, cell or composition that is in a form that does not exist in nature. An isolated polypeptide, antibody, polynucleotide, vector, cell or composition includes those that have been purified to the extent that they are no longer in the form in which they exist in nature. In some aspects, an isolated antibody, polynucleotide, vector, cell or composition is substantially pure. As used herein, "substantially pure" refers to a material that is at least 50% pure (i.e., free of contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.

[0118] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interspersed with non-amino acids. The term also encompasses amino acid polymers that have been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included in the definition are, for example, polypeptides containing one or more analogs of amino acids (including, for example, non-natural amino acids, etc.) and other modifications known in the art. It should be understood that because the polypeptides of the present disclosure are based on antibodies, in certain aspects, the polypeptides may appear as single chains or associated chains.

[0119] "Sequence identity" refers to the degree of identity between two sequences (e.g., amino acid sequences or nucleic acid sequences). Percent identity can be determined by comparing two sequences, introducing gaps to maximize the identity between the sequences. Alignments can be generated using programs known in the art. For purposes herein, nucleotide sequence alignments can be performed using the blastn program set to default parameters, and amino acid sequence alignments can be performed using the blastp program set to default parameters (see National Center for Biotechnology Information (NCBI), global website ncbi.nlm.nih.gov).

[0120] As used herein, the term "host cell" can be any type of cell, such as a primary cell, a cultured cell, or a cell from a cell line. In specific aspects, the term "host cell" refers to a cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. For example, the progeny of such a cell may differ from the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in the offspring or the integration of the nucleic acid molecule into the host cell genome.

[0121] The term "pharmaceutical composition" refers to a preparation in a form that permits the biological activity of the active ingredient to be effective, and which contains no additional components that are unacceptably toxic to a subject to which the composition would be administered. The composition may be sterile.

[0122] As used herein, the terms "administer / administering / administration" and the like refer to methods (e.g., intravenous administration) that can be used to deliver a drug (e.g., an anti-CD94 antibody or antigen-binding fragment thereof) to a desired site of biological action. Administration techniques that can be employed with the agents and methods described herein can be found in, for example, Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition, Pergamon; and Remington's, Pharmaceutical Sciences, current edition, Mack Publishing Co., Easton, Pa.

[0123] As used herein, the terms "subject" and "patient" are used interchangeably. The subject can be an animal. In some aspects, the subject can be a mammal, such as a non-human animal (e.g., a cow, pig, horse, cat, dog, rat, mouse, monkey or other primate, etc.). In some aspects, the subject is a human.

[0124] As used herein, the term "nucleic acid" or "polynucleotide" refers to nucleotides and / or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments produced by polymerase chain reaction (PCR), and fragments produced by any of ligation, rupture, endonuclease action and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally occurring nucleotides (such as DNA and RNA) or naturally occurring nucleotide analogs (such as enantiomeric forms of naturally occurring nucleotides) or a combination of the two. Modified nucleotides can have changes in sugar moieties and / or pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyls with halogens, alkyls, amines and azidos, or sugars can be functionalized as ethers or esters. In addition, the entire sugar moiety can be replaced by spatially and electronically similar structures such as azasugars and carbocyclic sugar analogs. Modification examples of base moieties include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substituents. Nucleic acid monomers can be connected by phosphodiester bonds or analogs of such bonds. Nucleic acids can be single-stranded or double-stranded.

[0125] The term "chimeric antigen receptor" (CAR) refers to a chimeric molecule comprising a binding domain (e.g., a binding domain may include an antibody or its antigen binding fragment specific to a desired antigen (e.g., CD94)) and a T cell receptor activating intracellular domain that binds to a component (e.g., a ligand) present on a target cell. In some aspects, CAR exhibits specific anti-target cell immune activity. In some aspects, CAR may include an extracellular ligand binding domain (e.g., a single-chain antibody binding domain (scFv)) fused to an intracellular signaling domain of a T cell antigen receptor complex ζ chain. In some aspects, CAR may include an extracellular ligand binding domain, a hinge, a transmembrane domain, and a cytoplasmic domain. In some aspects, the cytoplasmic domain includes a co-stimulatory domain (e.g., 4-1BB, CD28, or OX40) and a signaling domain (e.g., CD3ζ). In some aspects, when CAR is expressed in T cells, antigen recognition can be redirected according to the specificity of the antibody.

[0126] The term "vector" as used herein includes but is not limited to viral vectors, plasmids, RNA vectors or linear or circular DNA or RNA molecules, which may include chromosomes, non-chromosomes, semi-synthetic or synthetic nucleic acids. In some cases, vectors are those vectors capable of autonomous replication (episomal vectors) and / or expression of nucleic acids (expression vectors) connected thereto. A large number of suitable vectors are well known to those skilled in the art and are commercially available. Viral vectors include retroviruses, adenoviruses, parvoviruses (e.g., adeno-associated viruses), coronaviruses, negative-strand RNA viruses such as orthomyxoviruses (e.g., influenza viruses), rhabdoviruses (e.g., rabies viruses and vesicular stomatitis viruses), paramyxoviruses (e.g., measles viruses and Sendai viruses), positive-strand RNA viruses such as picornaviruses and alphaviruses, and double-stranded DNA viruses, including adenoviruses, herpes viruses (e.g., herpes simplex viruses type 1 and type 2, Epstein-Barr viruses, cytomegaloviruses) and poxviruses (e.g., vaccinia, fowlpox and canarypox). Other viruses include, for example, Norwalk virus, Togavirus, Flavivirus, Reovirus, Papovavirus, Hepadnavirus and Hepatitis virus.Examples of retroviruses include: avian leukosis-sarcoma virus, mammalian C virus, B virus, D virus, HTLV-BLV group and lentivirus.

[0127] "Costimulatory domain" or "costimulatory molecule" refers to a cognate binding partner on a T cell, which specifically binds to a costimulatory ligand to mediate a costimulatory response (e.g., a proliferative response) of the cell. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, and Toll ligand receptors. Examples of costimulatory molecules include CD27, CD28, CD8, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand specifically bound to CD83, etc. In some aspects, costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that promote effective immune responses.

[0128] "Costimulatory ligand" refers to a molecule on an antigen presenting cell, which specifically binds to the cognate costimulatory molecule on a T cell. In some aspects, a costimulatory ligand provides a signal other than the main signal provided by, for example, a TCR / CD3 complex and a MHC molecule of a load peptide, mediating a T cell response. In some aspects, T cell responses include, but are not limited to, proliferation activation, differentiation, etc. Costimulatory ligands may include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligands (ICOS-L), intercellular adhesion molecules (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, an agonist or antibody in conjunction with a Toll ligand receptor, and a ligand specifically bound to B7-H3.

[0129] A "co-stimulatory signal" refers to a signal that, in conjunction with a primary signal (eg, TCR / CD3 ligation), results in T cell proliferation and / or up- or down-regulation of molecules.

[0130] As used herein, the term "extracellular ligand binding domain" refers to an oligopeptide or polypeptide that is capable of binding a ligand (e.g., a cell surface molecule). For example, an extracellular ligand binding domain can be selected to recognize a ligand that is a cell surface marker on a target cell associated with a particular disease state (e.g., cancer). Examples of cell surface markers that can act as ligands include cell surface markers associated with viral, bacterial and parasitic infections, autoimmune diseases, and cancer cells.

[0131] The "signal transduction domain" or "signaling domain" used herein for CAR is responsible for intracellular signal transduction after the extracellular ligand binding domain binds to the target. In some aspects, the signal transduction domain used in CAR can cause the activation of immune cells and immune responses. In other words, the signal transduction domain can be responsible for the activation of at least one normal effector function of immune cells expressing CAR. For example, the effector function of T cells can be cytolytic activity or auxiliary activity (including the secretion of cytokines). Therefore, the signal transduction domain can refer to the part of the protein that transduces the effector function signal and instructs the cell to perform a specific function. Examples of signal transduction domains for CAR can be cytoplasmic sequences of T cell receptors and co-receptors, which work together to start signal transduction after antigen receptor engagement, as well as any derivatives or variants of these sequences and any synthetic sequences with the same functional capabilities. In some cases, the signal transduction domain contains two different types of cytoplasmic signaling sequences, one that initiates antigen-dependent primary activation, and one that provides secondary or costimulatory signals in an antigen-independent manner. The primary cytoplasmic signaling sequence can include a signaling motif called an immunoreceptor tyrosine-based activation motif (ITAM).

[0132] "ITAM" refers to a signaling motif found in the cytoplasmic tail of a variety of receptors, which can serve as a binding site for syk / zap70-like tyrosine kinases. Exemplary ITAMs include those derived from TCRζ, FcRγ, FcRβ, FcRε, CD3γ, CD3δ, CD3ε, CD3ζ, CD5, CD22, CD79a, CD79b, and CD66d. In some aspects, the signaling domain of CAR may include a CD3ζ signaling domain.

[0133] "Transmembrane region" or "transmembrane domain" used herein is a part of CAR, which anchors the extracellular binding portion to the plasma membrane of immune effector cells and promotes the binding of the binding domain to the target antigen. In some aspects, the transmembrane domain can be a CD3ζ transmembrane domain, but other transmembrane domains that can be used include those transmembrane domains obtained from CD8α, CD4, CD28, CD45, CD9, CD16, CD22, CD33, CD64, CD80, CD86, CD134, CD137 or CD154.

[0134] The binding domain of CAR may be followed by a "spacer" or "hinge", which refers to the region where the antigen binding domain is separated or removed from the effector cell surface. In some aspects, the hinge enables cell / cell contact, antigen binding and activation (Patel et al., Gene Therapy, 1999; 6: 412-419). The hinge region in CAR may be located between the transmembrane (TM) domain and the binding domain. In some aspects, the hinge region is an immunoglobulin hinge region and may be a wild-type immunoglobulin hinge region or an altered wild-type immunoglobulin hinge region. Other exemplary hinge regions used in CAR disclosed herein may include hinge regions derived from the extracellular region of type 1 membrane proteins (e.g., CD8α, CD4, CD28, and CD7), which may be wild-type hinge regions from these molecules or may be altered. In some aspects, the hinge region includes a CD8α hinge.

[0135] It should be understood that wherever the present disclosure describes an aspect with the phrase "comprising," other similar aspects disclosed with "consisting of" and / or "consisting essentially of" are also provided.

[0136] The following examples are for illustrative purposes only and do not limit the scope of the claimed aspects.

[0137] II. Anti-CD94 Antibodies and Antigen-Binding Fragments Thereof

[0138] In some aspects, antibodies (e.g., monoclonal antibodies) and antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) are provided herein. In some aspects, the amino acid sequence of human CD94 comprises SEQ ID NO: 31 (see RefSeq Accession No. NP_001107868.2).

[0139] In some aspects, the antibodies or antigen-binding fragments thereof provided herein bind to CD94 and comprise six CDRs (e.g., CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3). The CDRs can be determined by various algorithms in the art such as IMGT (Table 1), abYsis (Table 2), and Kabat (Table 3).

[0140] For example, the International Immunogenetics Information System (http: / / www.imgt.org) Based on the IMGT numbering of all immunoglobulins and T-cell receptor V-REGIONs from all species ( the internationalImMunoGeneTics information Lefranc MP et al., (1991) Nucleic Acids Res. 27(1):209-12; Ruiz M et al., (2000) Nucleic Acids Res. 28(1):219-21; Lefranc MP (2001) Nucleic Acids Res. 29(1):207-9; Lefranc MP (2003) Nucleic Acids Res. 31(1):307-10; Lefranc MP et al., (2005) Dev. Comp. Immunol. 29(3): 185-203; Kaas Q et al., (2007) Briefings in Functional Genomics&Proteomics, 6(4): 253-64).

[0141] The abYsis algorithm compiles antibody protein sequences from EMBLIG, which contains antibody information extracted from the EMBL-ENA database, the Kabat collection, and the Protein Data Bank (Swindells MB et al. (2017) J Mol Biol. 2017 Feb 3; 429(3): 356-364).

[0142] The Kabat definition is based on sequence variability and is the most commonly used definition (Kabat EA et al., supra).

[0143] Table 1 - IMGT CDR amino acid sequences

[0144]

[0145] Table 2-abYsis CDR amino acid sequences

[0146]

[0147] Table 3 - Kabat CDR amino acid sequences

[0148]

[0149] In some aspects, provided herein are antibodies or antigen-binding fragments thereof (e.g., anti-CD94 specific antibodies) that are capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0150] In some aspects, an antibody or antigen-binding fragment thereof capable of binding to CD94 (e.g., an anti-CD94 specific antibody) comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO:3, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6, a CDR L2 comprising the amino acid sequence YTS, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:8.

[0151] In some aspects, an antibody or antigen-binding fragment thereof capable of binding to CD94 (e.g., an anti-CD94 specific antibody) comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 22, a CDRL2 comprising the amino acid sequence shown in SEQ ID NO: 23, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0152] In some aspects, an antibody or antigen-binding fragment thereof capable of binding to CD94 (e.g., an anti-CD94 specific antibody) comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 22, a CDRL2 comprising the amino acid sequence shown in SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0153] In some aspects, antibodies or antigen-binding fragments thereof capable of binding to CD94 (e.g., anti-CD94 specific antibodies) comprise a heavy chain variable region (VH) and a light chain variable region (VL). In some aspects, VH comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 1. In some aspects, VL comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 2.

[0154] In some aspects, antibodies or antigen-binding fragments thereof capable of binding to CD94 (e.g., anti-CD94 specific antibodies) comprise a heavy chain variable region (VH) and a light chain variable region (VL). In some aspects, VH comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to SEQ ID NO: 1. In some aspects, VL comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to SEQ ID NO: 2.

[0155] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 1.

[0156] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having at least 99% identity with the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 2.

[0157] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having about 85% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 1.

[0158] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having about 85% identity to the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 2.

[0159] In some aspects, provided herein are antibodies or antigen-binding fragments thereof (e.g., anti-CD94-specific antibodies) that are capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: i) CDR H1, CDR H2, and CDR H3 comprising the CDR H1, CDR H2, and CDR H3 amino acid sequences of SEQ ID NO: 1; and ii) CDR L1, CDR L2, and CDR L3 comprising the CDR L1, CDR L2, and CDR L3 amino acid sequences of SEQ ID NO: 2.

[0160] In some aspects, the CDRs are Kabat-defined CDRs, Chothia-defined CDRs, AbM-defined CDRs, or IMGT-defined CDRs.

[0161] In some aspects, the antibody or antigen-binding fragment thereof is human, humanized, or chimeric.

[0162] In some aspects, the antibody or antigen-binding fragment thereof is an IgG antibody.

[0163] In some aspects, the IgG antibody is an IgG1 antibody or an IgG4 antibody.

[0164] In some aspects, the antibody is an antigen-binding fragment of an antibody.

[0165] In some aspects, the fragment is selected from the group consisting of Fab, F(ab')2, Fv, scFv, scFv-Fc, dsFv and a single domain molecule.

[0166] In some aspects, the fragment is a scFv.

[0167] In some aspects, the fragment is a Fab.

[0168] In some aspects, the fragment is an intrabody.

[0169] In some aspects, the antigen binding fragment lacks an Fc region.

[0170] In some aspects, the antibody or antigen-binding fragment thereof comprises VH and VL on the same polypeptide chain.

[0171] In some aspects, the VH and VL are connected by a linker.

[0172] In some aspects, the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.

[0173] In some aspects, the antibody or antigen-binding fragment thereof is a bispecific antibody. The antibody can be in the form of scFv, Fab, F(ab)2 or IgG conjugated to anti-CD3 antibody, anti-CD16 antibody or other molecule to mediate effector response against target cells expressing CD94 through T, NK or macrophage immune cells.

[0174] In some aspects, the antibodies or antigen-binding fragments thereof disclosed herein can be described by their individual VL domains or by their individual VH domains. See, e.g., Rader C et al., (1998) PNAS 95:8910-8915, which is incorporated herein by reference in its entirety, describing the humanization of mouse anti-αvβ3 antibodies by identifying complementary light chains or heavy chains from human light chain or heavy chain libraries, respectively, thereby generating humanized antibody variants with as high or higher affinity as the original antibody. See also Clackson T et al., (1991) Nature 352:624-628, which is incorporated herein by reference in its entirety, describing methods for generating antibodies that bind to specific antigens by using specific VL domains (or VH domains) and screening complementary variable domain libraries. See also Kim SJ & Hong HJ, (2007) J Microbiol 45:572-577, which is incorporated herein by reference in its entirety, describing a method for producing antibodies that bind to a specific antigen by using a specific VH domain and screening a library of complementary VL domains (e.g., a human VL library); the selected VL domain can in turn be used to guide the selection of additional complementary (e.g., human) VH domains.

[0175] In some aspects, the CDRs of an antibody or antigen-binding fragment thereof can be identified according to the Chothia numbering scheme, which refers to the positions of immunoglobulin structural loops (see, e.g., Chothia C and Lesk AM, (1987), J Mol Biol 196:901-917; Al-Lazikani B et al., (1997) J Mol Biol 273:927-948; Chothia C et al., (1992) J Mol Biol 227:799-817; Tramontano A et al., (1990) J Mol Biol 215(1):175-82; and U.S. Pat. No. 7,709,226). Generally, when using the Kabat numbering convention, the Chothia CDR-H1 loop occurs at heavy chain amino acids 26 to 32, 33, or 34, the Chothia CDR-H2 loop occurs at heavy chain amino acids 52 to 56, and the Chothia CDR-H3 loop occurs at heavy chain amino acids 95 to 102, while the Chothia CDR-L1 loop occurs at light chain amino acids 24 to 34, the Chothia CDR-L2 loop occurs at light chain amino acids 50 to 56, and the Chothia CDR-L3 loop occurs at light chain amino acids 89 to 97. When numbered using the Kabat numbering convention, the ends of the Chothia CDR-H1 loop vary between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if both 35A and 35B are absent, the loop ends at 32; if only 35A is present, the loop ends at 33; and if both 35A and 35B are present, the loop ends at 34).

[0176] In some aspects, antibodies and antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) and comprise the Chothia VH and VL CDRs of the antibody are provided herein. In some aspects, antibodies or antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) comprise one or more CDRs, wherein the Chothia and Kabat CDRs have the same amino acid sequence. In some aspects, antibodies and antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) and comprise a combination of Kabat CDRs and Chothia CDRs are provided herein.

[0177] In some aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the IMGT numbering system described in Lefranc MP, (1999) The Immunologist 7: 132-136 and Lefranc MP et al., (1999) Nucleic Acids Res 27: 209-212. According to the IMGT numbering scheme, CDR H1 is located at positions 26 to 35, CDR H2 is located at positions 51 to 57, CDR H3 is located at positions 93 to 102, CDR L1 is located at positions 27 to 32, CDR L2 is located at positions 50 to 52, and CDR L3 is located at positions 89 to 97. In some aspects, provided herein are antibodies and antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) and comprise the IMGT VH and VL CDRs of the antibodies listed in Tables 3 and 4, e.g., as described in Lefranc MP (1999) supra and Lefranc MP et al., (1999) supra.

[0178] In some aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to MacCallum RM et al., (1996) J Mol Biol 262:732-745. See also, for example, Martin A. "Protein Sequence and Structure Analysis of Antibody Variable Domains," in Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). In some aspects, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) determined by the method of MacCallum RM et al.

[0179] In some aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the AbM numbering scheme, which refers to the AbM hypervariable regions that represent a compromise between Kabat CDRs and Chothia structural loops and is used by Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.). In some aspects, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CD94 (e.g., human CD94) that are determined by the AbM numbering scheme.

[0180] In some aspects, the antibodies or antigen-binding fragments thereof disclosed herein are isolated antibodies or antigen-binding fragments thereof. In some aspects, the antibodies or antigen-binding fragments thereof disclosed herein are monoclonal antibodies or antigen-binding fragments thereof. In some aspects, the antibodies or antigen-binding fragments thereof disclosed herein are not polyclonal antibodies or antigen-binding fragments thereof.

[0181] In some aspects, the antigen-binding fragments disclosed herein that immunospecifically bind to CD94 (e.g., human CD94) are selected from the group consisting of Fab, Fab', F(ab')2, and scFv, wherein Fab, Fab', F(ab')2, or scFv comprises the heavy chain variable region sequence and the light chain variable region sequence of the anti-CD94 antibody or antigen-binding fragment thereof disclosed herein. Fab, Fab', F(ab')2, or scFv can be produced by any technique known to those skilled in the art. In some aspects, Fab, Fab', F(ab')2, or scFv further comprises a portion that extends the half-life of the antibody in vivo. The portion is also referred to as a "half-life extending portion". Any portion known to those skilled in the art for extending the half-life of Fab, Fab', F(ab')2, or scFv in vivo can be used. For example, the half-life extending portion may include an Fc region, a polymer, albumin, or an albumin binding protein or compound. Polymers can include natural or synthetic, optionally substituted straight or branched polyalkylene, polyalkenylene, polyoxyalkylene, polysaccharide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, methoxypolyethylene glycol, lactose, amylose, dextran, glycogen or its derivatives. Substituents can include one or more hydroxyl, methyl or methoxy groups. In some aspects, Fab, Fab', F(ab')2 or scFv can be modified by adding one or more C-terminal amino acids to connect the half-life extension part. In some aspects, the half-life extension part is polyethylene glycol or human serum albumin. In some aspects, Fab, Fab', F(ab')2 or scFv are fused with the Fc region.

[0182] In some aspects, the anti-CD94 antibodies or antigen-binding fragments thereof disclosed herein are bispecific antibodies or antigen-binding fragments thereof.

[0183] The anti-CD94 antibody or antigen-binding fragment thereof can be fused or conjugated (e.g., covalently or non-covalently linked) to a detectable label or substance. Examples of detectable labels or substances include enzyme labels, such as glucose oxidase; radioactive isotopes, such as iodine ( 125 I. 121 I), carbon ( 14 C) Sulfur ( 35 S), tritium ( 3 H), Indium ( 121 In) and technetium ( 99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. Such labeled antibodies or antigen-binding fragments thereof can be used to detect CD94 (e.g., human CD94) protein.

[0184] III. Anti-CD94 Chimeric Antigen Receptor

[0185] Chimeric antigen receptors (CARs) redirect T cells specifically to antibody-recognized antigens expressed on the surface of cells, such as cancer cells.

[0186] In some aspects, the present disclosure includes a chimeric antigen receptor (CAR) specific for CD94. In some aspects, the CAR disclosed herein includes an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (e.g., a signaling domain derived from CD3ζ or FcRγ), and / or one or more costimulatory signaling domains derived from costimulatory molecules, such as, but not limited to, 4-1BB, CD28, or OX40. In some aspects, CAR includes a hinge or spacer between an extracellular binding domain and a transmembrane domain, such as a CD8α hinge.

[0187] In some aspects, provided herein is a chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising an antigen binding domain capable of binding to CD94; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain. In some aspects, the antigen binding domain comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0188] In some aspects, the antigen binding domain comprises: a CDRH1 comprising the amino acid sequence shown in SEQ ID NO:3, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6, a CDRL2 comprising the amino acid sequence YTS, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:8.

[0189] In some aspects, the antigen binding domain comprises: a CDRH1 comprising the amino acid sequence shown in SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:22, a CDR L2 comprising the amino acid sequence shown in SEQ ID NO:23, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:8.

[0190] In some aspects, the antigen binding domain comprises: a CDRH1 comprising the amino acid sequence shown in SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:22, a CDR L2 comprising the amino acid sequence shown in SEQ ID NO:24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:8.

[0191] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:9.

[0192] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:9.

[0193] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:56.

[0194] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:56.

[0195] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:57.

[0196] In some aspects, the chimeric antigen receptor comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:57.

[0197] In some aspects, the chimeric antigen receptor comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:2.

[0198] In some aspects, the VH comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1. In some aspects, the VL comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2.

[0199] In some aspects, the VH comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 1. In some aspects, the VL comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 2.

[0200] In some aspects, the VH comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 1.

[0201] In some aspects, the VL comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 2.

[0202] In some aspects, the VH comprises an amino acid sequence having about 85% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the VH comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 1.

[0203] In some aspects, the VL comprises an amino acid sequence that is about 85% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is about 90% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is about 95% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is about 98% identical to the amino acid sequence of SEQ ID NO: 2. In some aspects, the VL comprises an amino acid sequence that is about 99% identical to the amino acid sequence of SEQ ID NO: 2.

[0204] In some aspects, the antigen binding domain is a scFv. In some aspects, the scFv comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% sequence identity to SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:33.

[0205] In some aspects, the scFv comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is about 85% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is about 90% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is about 95% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is about 98% identical to the amino acid sequence of SEQ ID NO: 33. In some aspects, the scFv comprises an amino acid sequence that is about 99% identical to the amino acid sequence of SEQ ID NO:33.

[0206] In some aspects, the costimulatory domain includes a 4-1BB costimulatory domain. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% sequence identity with SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:37.

[0207] In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 37. In some aspects, the 4-1BB co-stimulatory domain comprises an amino acid sequence having about 85% identity to the amino acid sequence SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having about 90% identity to the amino acid sequence SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having about 95% identity to the amino acid sequence SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having about 98% identity to the amino acid sequence SEQ ID NO: 37. In some aspects, the 4-1BB costimulatory domain comprises an amino acid sequence having about 99% identity to the amino acid sequence SEQ ID NO: 37.

[0208] In some aspects, the costimulatory domain comprises a CD28 costimulatory domain. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% sequence identity to SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:52.

[0209] In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 85% identity to the amino acid sequence SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 52. In some aspects, the CD28 costimulatory domain comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 52.

[0210] In some aspects, the costimulatory domain comprises an OX40 costimulatory domain. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:53.

[0211] In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is about 85% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is about 90% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is about 95% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is about 98% identical to the amino acid sequence of SEQ ID NO: 53. In some aspects, the OX40 costimulatory domain comprises an amino acid sequence that is about 99% identical to the amino acid sequence of SEQ ID NO: 53.

[0212] In some aspects, the hinge, the transmembrane domain, or both are from a CD8 alpha polypeptide.

[0213] In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:35.

[0214] In some aspects, the CD8α hinge domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:35. In some aspects, the CD8α hinge domain comprises an amino acid sequence having about 85% identity to the amino acid sequence SEQ ID NO:35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 35. In some aspects, the CD8 alpha hinge domain comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 35.

[0215] In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 36. In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:36.

[0216] In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8α transmembrane domain comprises an amino acid sequence having about 85% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 36. In some aspects, the CD8 alpha transmembrane domain comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 36.

[0217] In some aspects, the signaling domain comprises a CD3 zeta signaling domain. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:38.

[0218] In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence that is about 85% identical to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 38. In some aspects, the CD3 zeta signaling domain comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 38.

[0219] In some aspects, the chimeric antigen receptor comprises any of the amino acid sequences shown in Table 4 or a combination thereof.

[0220] Table 4 - Exemplary chimeric antigen receptor amino acid sequences

[0221]

[0222]

[0223]

[0224] In some aspects, the chimeric antigen receptor comprises any nucleic acid sequence shown in Table 5 or a combination thereof.

[0225] Table 5 - Exemplary chimeric antigen receptor nucleic acid sequences

[0226]

[0227]

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234] In some aspects, the binding domain or extracellular domain of CAR provides CAR with the ability to bind to the target antigen of interest. The binding domain (e.g., ligand binding domain or antigen binding domain) can be any protein, polypeptide, oligopeptide or peptide with the ability to specifically recognize and bind biomolecules (e.g., cell surface receptors or tumor proteins, or components thereof). The binding domain may include any naturally occurring, synthetic, semi-synthetic or recombinantly produced binding partners of the biomolecule of interest. For example, and as further disclosed herein, the binding domain may be an antibody light chain and heavy chain variable region, or the light chain and heavy chain variable region may be connected together in a single-chain form and in any orientation (e.g., VL-VH or VH-VL). It is known that there are a variety of assays that can be used to identify the binding domains of the present disclosure that are specifically bound to a specific target, including Western blot, ELISA, flow cytometry or surface plasmon resonance analysis (e.g., using BIACORE analysis). The target can be a clinically significant antigen, for which the antigen is expected to trigger an effector immune response that causes tumor killing. In some aspects, the target antigen of the binding domain of the chimeric antigen receptor is CD94 protein.

[0235] Illustrative ligand binding domains include antigen binding proteins, such as antigen binding fragments of antibodies, such as scFv, the extracellular domain of receptors, ligands of cell surface molecules / receptors or their receptor binding domains and tumor binding proteins. In some aspects, the antigen binding domains included in the CAR of the present disclosure can be variable regions (Fv), CDR, Fab, scFv, VH, VL, domain antibody variants (dAb), camel antibodies (VHH) and other antigen-specific binding domains from other protein scaffolds.

[0236] In some aspects, the binding domain of CAR is an anti-CD94 single-chain antibody (scFv), and can be a mouse, chimeric, human or humanized scFv. Single-chain antibodies can be cloned from the V region genes of hybridomas that are specific to the desired target. Techniques that can be used to clone variable region heavy chains (VH) and variable region light chains (VL) have been disclosed in, for example, Orlandi et al., PNAS, 1989; 86: 3833-3837. Therefore, in some aspects, the binding domain includes an antibody-derived binding domain, but can be a non-antibody-derived binding domain. The antibody-derived binding domain can be a fragment of an antibody or a genetically engineered product of one or more antibody fragments that participate in binding to an antigen.

[0237] In some aspects, the CAR of the present disclosure may include a joint between one or more domains, for example, a joint added for the proper spacing and conformation of the molecule. For example, in some aspects, there may be a joint between the binding domains VH or VL. In some aspects, the length of the joint may be 1-10 amino acids. In some aspects, the length of the joint between any domains of the chimeric antigen receptor may be 1-20 or 20 amino acids. In this regard, the length of the joint may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. In some aspects, the length of the joint may be 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. Also included herein are the ranges including the numbers described herein, such as joints with a length of 10-30 amino acids.

[0238] In some aspects, the joint suitable for CAR disclosed herein is a flexible joint. Suitable joints can be easily selected and can have any suitable different lengths, such as 1 amino acid (e.g., Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, and can be 1, 2, 3, 4, 5, 6 or 7 amino acids.

[0239] Exemplary flexible linkers can include glycine polymers (G) n, glycine-serine polymers (where n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured and can therefore be used as neutral tethers between domains of fusion proteins (e.g., CAR disclosed herein). Glycine can enter significantly more phi-psi spaces than alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). Ordinary technicians will recognize that the design of CAR can include all or part of a flexible linker, so that the linker can include a flexible linker and one or more parts that confer a less flexible structure to provide the desired CAR structure. Specific linkers include (G4S) n linkers, where n = 1-3. In some aspects, the linker comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 34. In some aspects, the linker comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 34. In some aspects, the linker comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:34.

[0240] In some aspects, the linker comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having about 85% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having about 90% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO:34. In some aspects, the linker comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 34. In some aspects, the linker comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO:34.

[0241] In some aspects, the membrane spaning region or domain is part of CAR, which anchors the extracellular binding part to the plasma membrane of immune effector cells, and promotes the binding of the binding domain to the target antigen. In some aspects, the membrane spaning domain can be a CD3ζ membrane spaning domain, but other membrane spaning domains that can be used include those obtained from CD8α, CD4, CD28, CD45, CD9, CD16, CD22, CD33, CD64, CD80, CD86, CD134, CD137 or CD154. In some aspects, the membrane spaning domain is the membrane spaning domain of CD8α. In some aspects, the membrane spaning domain is synthetic, in which case it mainly comprises hydrophobic residues, such as leucine and valine.

[0242] Signaling through the T cell receptor alone is not sufficient to fully activate T cells. A co-stimulatory signal or signaling domain should also be present to activate T cells.

[0243] Examples of signal transduction domains for CAR can be cytoplasmic sequences of T cell receptors and co-receptors, which work together to initiate signal transduction after antigen receptor engagement, as well as any derivatives or variants of these sequences and any synthetic sequences with the same functional capabilities. In some cases, the signal transduction domain includes two different types of cytoplasmic signal transduction sequences, one that initiates antigen-dependent primary activation, and one that provides secondary or costimulatory signals in an antigen-independent manner. The primary cytoplasmic signal transduction sequence may include a signal transduction motif known as an immunoreceptor tyrosine-based activation motif (ITAM). ITAM can be found in the cytoplasmic tail of a variety of receptors that are binding sites for syk / zap70 class tyrosine kinases.

[0244] Exemplary ITAMs may include those derived from TCR ζ, FcR γ, FcR β, FcR ε, CD3 γ, CD3 δ, CD3 ε, CD3 ζ, CD5, CD22, CD79a, CD79b and CD66d. In some aspects, the signal transduction domain of CAR may include a CD3 ζ signaling domain.

[0245] In some aspects, CAR disclosed herein may include, for example, a costimulatory domain derived from a costimulatory molecule.Costimulatory molecules may include, but are not limited to, MHC class I molecules, BTLA, and Toll ligand receptors. Examples of costimulatory molecules include, for example, CD27, CD28, CD8, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands specifically bound to CD83, etc. Costimulatory molecules may be cell surface molecules other than antigen receptors or their ligands, which can contribute to an effective immune response. Therefore, although the present disclosure provides exemplary costimulatory domains derived from 4-1BB, it is also contemplated that other costimulatory domains will be used together with CAR disclosed herein. One or more costimulatory signaling domains may be included to enhance the efficacy and amplification of T cells expressing CAR receptors disclosed herein. Intracellular signaling and costimulatory signaling domains may be connected in series to the carboxyl terminus of the transmembrane domain in any order.

[0246] In some aspects, the CAR disclosed herein may include a signal peptide. In some aspects, the signal peptide is a CD8 alpha signal peptide. In some aspects, the CD8 alpha signal peptide includes an amino acid sequence with at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 32. In some aspects, the CD8 alpha signal peptide includes an amino acid sequence with at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% sequence identity. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:32.

[0247] In some aspects, the CD8α signal peptide comprises an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 85% identity to the amino acid sequence SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 90% identity to the amino acid sequence SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 95% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 98% identity to the amino acid sequence of SEQ ID NO: 32. In some aspects, the CD8α signal peptide comprises an amino acid sequence having about 99% identity to the amino acid sequence of SEQ ID NO: 32.

[0248] Although it has been demonstrated that scFv-based CARs engineered to contain signaling domains from CD3 or FcRγ can provide potent signals for T cell activation and effector function, they are insufficient to elicit signals that promote T cell survival and expansion without accompanying co-stimulatory signals. Other CARs containing binding domains, hinges, transmembrane and signaling domains derived from CD3ζ or FcRγ and one or more co-stimulatory signaling domains (e.g., intracellular co-stimulatory domains derived from CD28, CD137, CD134, and CD278) can more effectively direct anti-tumor activity and increased cytokine secretion, lytic activity, survival, and proliferation in T cells expressing CARs in vitro and in animal models and cancer patients (Milone et al., Molecular Therapy, 2009; 17: 1453-1464; Zhong et al., Molecular Therapy, 2010; 18: 413-420; Carpenito et al., PNAS, 2009; 106: 3360-3365).

[0249] In some aspects, the CD94 binding CAR of the present disclosure comprises (a) an anti-CD94 scFv as a binding domain (e.g., an scFv having a binding region (e.g., CDR or variable domain) from an anti-CD94 antibody disclosed herein or an antigen-binding fragment thereof); (b) a hinge region (e.g., derived from human CD8α); (c) a transmembrane domain (e.g., a human CD8α transmembrane domain); and (d) a signaling domain (e.g., a human T cell receptor CD3ζ chain signaling domain), and optionally one or more costimulatory signaling domains, such as a 4-1BB costimulatory domain, a CD28 costimulatory domain, or an OX40 costimulatory domain. In some aspects, the different protein domains are arranged in the following order from amino to carboxyl terminus: a binding domain, a hinge domain, and a transmembrane domain. The intracellular signaling domain and the optional costimulatory signaling domain are connected in series to the transmembrane carboxyl terminus in any order to form a single-chain chimeric polypeptide.

[0250] In some aspects, the nucleic acid construct encoding CD94 binding CAR is a chimeric nucleic acid molecule comprising different coding sequences, such as (5' to 3') human anti-CD94 scFv, human CD8 α-hinge region, human CD8 α transmembrane domain and CD3 ζ signaling domain coding sequence. In some aspects, the nucleic acid construct encoding CD94 binding CAR is a chimeric nucleic acid molecule comprising different coding sequences, such as (5' to 3') human anti-CD94 scFv, human CD8 α-hinge, human CD8 α transmembrane domain, 4-1BB costimulatory domain and CD3 ζ signaling domain coding sequence.

[0251] In some aspects, the polynucleotide encoding the CAR disclosed herein is inserted into a vector. In some aspects, the vector used herein is a vector into which a polynucleotide encoding a protein can be covalently inserted to achieve expression of the protein and / or cloning of the polynucleotide. The isolated polynucleotide can be inserted into a vector using any suitable method known in the art, such as, but not limited to, the vector can be digested with an appropriate restriction enzyme, and then it can be connected to an isolated polynucleotide with a matching restriction end. In some aspects, the expression vector has the ability to incorporate and express a heterologous or modified nucleic acid sequence, which encodes at least a portion of a gene product that can be transcribed in a cell. In most cases, the RNA molecule is subsequently translated into protein. The expression vector may contain a variety of control sequences, which refer to nucleic acid sequences that are transcribed and may translate operably connected coding sequences in a specific host organism. In addition to the control sequences that control transcription and translation, vectors and expression vectors may also contain nucleic acid sequences that perform other functions, as discussed below. The expression vector may include additional elements, for example, the expression vector may have two replication systems so that it can be maintained in two organisms, such as for expression in human cells and for cloning and amplification in prokaryotic hosts.

[0252] The expression vector may have 5' upstream and 3' downstream regulatory elements, such as promoter sequences (e.g., CMV, PGK or EF1α promoters), ribosome recognition and binding TATA box and 3'UTR AAUAAA transcription termination sequence, so as to effectively carry out gene transcription and translation in their respective host cells. Other suitable promoters may include constitutive promoters of simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), HIV LTR promoter, MoMuLV promoter, avian leukosis virus promoter, EBV immediate early promoter and Rous sarcoma virus promoter. Human gene promoters may also be used, including but not limited to actin promoter, myosin promoter, hemoglobin promoter and creatine kinase promoter. In some aspects, inducible promoters are also considered as part of the vector expressing the chimeric antigen receptor. This provides a molecular switch that can start the expression of the polynucleotide sequence of interest or turn off the expression. Examples of inducible promoters include but are not limited to metallothionein promoters, glucocorticoid promoters, progesterone promoters or tetracycline promoters.

[0253] The expression vector may have additional sequences, such as 6x-histidine, c-Myc and FLAG tags, which are incorporated into the expressed CAR. Therefore, the expression vector may be engineered to contain 5' and 3' non-translated regulatory sequences, which may sometimes serve as enhancer sequences, promoter regions and / or terminator sequences that can promote or enhance the effective transcription of the nucleic acid of interest carried on the expression vector. The expression vector may also be engineered to replicate and / or express function (e.g., transcription and translation) in a specific cell type, cell position or tissue type. The expression vector may include a selective marker for maintaining the vector in a host or recipient cell.

[0254] In some aspects, the vector is a plasmid, an autonomously replicating sequence, and a transposable element. Other exemplary vectors include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or artificial chromosomes (PAC) from P1 sources, phages such as lambda phages or M13 phages, and animal viruses. Examples of animal virus classes that can be used as vectors include, but are not limited to, retroviruses (including slow viruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (e.g., SV40). Examples of expression vectors are Lenti-X for expression in mammalian cells. TM Bicistronic Expression System (Neo) vector (Clontrch), pClneo vector (Promega); pLenti4 / V5-DEST for lentivirus-mediated gene transfer and expression in mammalian cells TM 、pLenti6 / V5-DEST TM And pLenti6.2N5-GW / lacZ (Invitrogen). The coding sequence of the CAR disclosed herein can be connected to such expression vectors to express chimeric proteins in mammalian cells.

[0255] In some aspects, in order to express CD94 binding CAR, a vector can be introduced into a host cell to allow the polypeptide to be expressed in the host cell. The expression vector may contain a variety of elements for controlling expression, including but not limited to a promoter sequence, a transcription start sequence, an enhancer sequence, a selective marker, and a signal sequence. As disclosed herein, a person of ordinary skill in the art may appropriately select these elements. For example, a promoter sequence may be selected to promote transcription of a polynucleotide in a vector. Suitable promoter sequences include but are not limited to T7 promoters, T3 promoters, SP6 promoters, β-actin promoters, EF1a promoters, CMV promoters, and SV40 promoters. An enhancer sequence may be selected to enhance transcription of a polynucleotide. A selective marker may be selected to allow a host cell into which a vector is inserted to be selected from a host cell into which a vector is not inserted, for example, a selective marker may be a gene that confers antibiotic resistance. A signal sequence may be selected to allow the expressed polypeptide to be transported outside the host cell.

[0256] In order to clone a polynucleotide, a vector can be introduced into a host cell (isolated host cell) to allow the vector itself to replicate, thereby amplifying the copies of the polynucleotide contained therein. The cloning vector can contain sequence components, generally including but not limited to a replication origin, a promoter sequence, a transcription initiation sequence, an enhancer sequence, and a selective marker. Those skilled in the art can appropriately select these elements. For example, a replication origin can be selected to promote autonomous replication of the vector in the host cell.

[0257] In some aspects, the disclosure provides a host cell containing an isolation of a vector provided herein. The host cell containing the vector can be used to express or clone the polynucleotide contained in the vector. Suitable host cells may include, but are not limited to, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells such as mammalian cells. Prokaryotic cells suitable for this purpose include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, such as E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescans, and Shigella, as well as Bacilli, such as B. subtilis and B. licheniformis, Pseudomonas, such as P. aeruginosa, and Streptomyces.

[0258] CAR of the present disclosure can be introduced into host cells using transfection and / or transduction techniques known in the art. The terms "transfection" and "transduction" used herein refer to the process of introducing exogenous nucleic acid sequences into host cells. Nucleic acids can be integrated into host cell DNA, or can be maintained outside the chromosome. Nucleic acids can be temporarily maintained or stably introduced. Transfection can be achieved by a variety of methods known in the art, including but not limited to calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection and gene gun method. Transduction refers to the use of viruses or retroviral vectors to deliver genes through viral infection rather than transfection. In some aspects, retroviral vectors are transduced by packaging the vector into a virion before contacting the cell. For example, the nucleic acid encoding CD94CAR carried by the retroviral vector can be transduced into the cell by infection and proviral integration.

[0259] In some aspects, the CARs of the present disclosure are introduced and expressed in immune effector cells, thereby redirecting their specificity to a target antigen of interest.

[0260] The present disclosure provides a method for manufacturing immune effector cells expressing CAR disclosed herein. In some aspects, immune effector cells are separated from individuals and genetically modified without further in vitro operation. Then, these cells can be directly re-applied to individuals. In some aspects, immune effector cells are first activated and stimulated to proliferate in vitro, and then genetically modified to express CAR. In this regard, immune effector cells can be cultivated before or after genetic modification (i.e., transduction or transfection to express CAR disclosed herein).

[0261] Before the immune effector cells disclosed herein are subjected to in vitro manipulation or genetic modification, a cell source can be obtained from a subject. Specifically, the immune effector cells used with the CAR disclosed herein include T cells. T cells can be obtained from many sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumor. In some aspects, many techniques known to technicians, such as FICOLL separation, can be used to obtain T cells from unit blood collected from subjects. In some aspects, cells from individual circulating blood are obtained by apheresis. Apheresis products generally contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells and platelets. In some aspects, cells collected by apheresis can be washed to remove the plasma portion, and the cells are placed in a suitable buffer or medium for subsequent treatment. In some aspects, cells are washed with PBS. In some aspects, the washed solution lacks calcium, and may lack magnesium or may lack many (if not all) divalent cations. It will be appreciated by those of ordinary skill in the art that the washing step can be accomplished by methods known to those of skill in the art, such as by using a semi-automatic flow-through centrifuge. After washing, the cells can be resuspended in a variety of biocompatible buffers or other saline solutions with or without buffers. In some aspects, unwanted components in the apheresis sample can be removed in the culture medium in which the cells are directly resuspended.

[0262] In some aspects, the monocytes are depleted by lysing the red blood cells (e.g., by PERCOLL TMGradient centrifugation) is used to separate T cells from peripheral blood mononuclear cells (PBMC). Specific subpopulations of T cells, such as CD28+, CD4+, CD8+, CD45RA+ and CD45RO+T cells, can be further separated by positive or negative selection techniques. For example, the enrichment of T cell populations obtained by negative selection can be achieved with a combination of antibodies for surface markers specific to negatively selected cells. One method used herein is to sort and / or select cells by negative magnetic immunoadhesion or flow cytometry, using a mixture of monoclonal antibodies for cell surface markers present on negatively selected cells. For example, in order to enrich CD4+ cells by negative selection, a mixture of monoclonal antibodies typically includes antibodies for CD14, CD20, CD1b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to separate the cell populations of interest used in the present disclosure.

[0263] PBMC can be used to carry out CAR genetic modification directly using the method disclosed herein. In some aspects, after separating PBMC, T lymphocytes are further separated, and in some aspects, cytotoxic T lymphocytes and helper T lymphocytes can be classified as primary T cells, memory T cells and effector T cell subsets before or after genetic modification and / or amplification. CD8+ cells can be obtained using standard methods. In some aspects, by identifying the cell surface antigens associated with each of these types of CD8+ cells, CD8+ cells are further classified into primary cells, central memory cells and effector cells. In some aspects, memory T cells are present in CD62L+ and CD62L- subgroups of CD8+ peripheral blood lymphocytes. After staining with anti-CD8 and anti-CD62L antibodies, PBMCs are classified into CD62L-CD8+ and CD62L+CD8+ parts. In some aspects, the expression of phenotypic markers of central memory TCM includes CD45RO, CD62L, CCR7, CD28, CD3 and CD127, and is negative for granzyme B. In some aspects, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some aspects, effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some aspects, naive CD8+ T lymphocytes are characterized by expressing phenotypic markers of naive T cells, including CD62L, CCR7, CD28, CD3, CD 127, and CD45RA.

[0264] In some aspects, CD4+T cells are further classified into subgroups. For example, CD4+T helper cells can be classified into naive cells, central memory cells, and effector cells by identifying cell populations with cell surface antigens. CD4+ lymphocytes can be obtained by standard methods.

[0265] Immune effector cells such as T cells can be genetically modified after being separated using known methods, or immune effector cells can be activated and amplified in vitro (or differentiated in the case of progenitor cells) before genetic modification. In another embodiment, immune effector cells such as T cells are genetically modified (e.g., transduced with a viral vector comprising a nucleic acid encoding CAR) using a chimeric antigen receptor disclosed herein, and then activated and amplified in vitro. Methods for activating and amplifying T cells are known in the art and are disclosed in, for example, U.S. Patent Nos. 6,905,874; 6,867,041; 6,797,514; WO2012079000. Typically, these methods include contacting PBMC or separated T cells with stimulants and co-stimulators such as anti-CD3 and anti-CD28 antibodies in a culture medium containing appropriate cytokines such as IL-2, and the stimulants and co-stimulators are generally attached to beads or other surfaces. Anti-CD3 and anti-CD28 antibodies attached to the same beads can be used as "alternative" antigen presenting cells (APCs). In some aspects, T cells may be activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those disclosed in US Pat. Nos. 6,040,177, 5,827,642, and WO2012129514.

[0266] Immune effector cells expressing CAR prepared as disclosed herein can be used in methods and compositions for adoptive immunotherapy according to known techniques, or in variants thereof that are obvious to those skilled in the art based on the present disclosure. For example, see U.S. Patent Application Publication No. 2003 / 0170238 of Gruenberg et al.; see also U.S. Patent No. 4,690,915 of Rosenberg.

[0267] In some aspects, the cells are formulated by first harvesting the cells from their culture medium, then washing and concentrating the cells in a therapeutically effective amount in a culture medium and container system suitable for administration (a "pharmaceutically acceptable" carrier). Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte™ A (Baxter), but 5% dextrose in water or Ringer's lactate solution can also be used. The infusion medium can be supplemented with human serum albumin.

[0268] Cells can be autologous or allogeneic for the patient being treated. If desired, treatment can also include administering mitogens (e.g., PHA) or lymphokines, cytokines and / or chemokines disclosed herein (e.g., IFN-γ, IL-2, IL-12, TNF-α, IL-18 and TNF-β, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1α, etc.) to enhance the induction of immune response.

[0269] The immune effector cell group expressing CAR disclosed herein can be administered alone, or as a pharmaceutical composition and a diluent and / or in combination with other components such as IL-2 or other cytokines or cell groups. In short, the pharmaceutical composition disclosed herein may include a population of immune effector cells expressing CAR, such as T cells disclosed herein, and a combination of one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such pharmaceutical compositions include buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The composition disclosed herein is preferably formulated for intravenous administration.

[0270] A humoral immune response mediated primarily by helper T cells that can activate B cells leading to antibody production can be induced. The type of immune response induced by the compositions of the present disclosure can be analyzed using a variety of techniques that are well documented in the art; for example, Current Protocols in Immunology, eds.: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober (2001) John Wiley & Sons, NY, NY.

[0271] In some aspects, provided herein are methods of treating cancer in an individual, the methods comprising administering to the individual a therapeutically effective amount of any of the chimeric antigen receptors provided herein.

[0272] In some aspects, the cancer is a leukemia. In some aspects, the cancer is a cancer that expresses CD94.

[0273] In some aspects, the leukemia is T-cell leukemia, T-cell large granular leukemia, natural killer cell large granular leukemia, or natural killer cell leukemia.

[0274] In some aspects, the cancer is lymphoma.

[0275] In some aspects, the lymphoma is T-cell lymphoma, extranodal natural killer / T-cell lymphoma, hepatosplenic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, or anaplastic large cell lymphoma.

[0276] In some aspects, the cancer is lung cancer, bladder cancer, or melanoma.

[0277] In some aspects, provided herein are methods of treating or preventing transplant rejection of a transplant in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the chimeric antigen receptors provided herein.

[0278] In some aspects, the transplant is an allogeneic transplant.

[0279] In some aspects, the transplant is an organ transplant.

[0280] In some aspects, the transplant is a hematopoietic cell transplant.

[0281] In some aspects, the transplant is induced pluripotent cell therapy.

[0282] In some aspects, provided herein are methods of modulating an immune response in a subject, the method comprising administering to the individual a therapeutically effective amount of an antibody or antigen-binding fragment thereof of any of the chimeric antigen receptors provided herein.

[0283] In some aspects, the immune response is enhanced.

[0284] In some aspects, the immune response is mediated by natural killer cells and / or T cells.

[0285] The method of administering the cell composition disclosed herein includes any effective method for directly causing the reintroduction of the ex vivo genetically modified immune effector cells expressing the CAR disclosed in the subject or the reintroduction of the genetically modified progenitor cells of the immune effector cells, wherein the progenitor cells differentiate into mature immune effector cells expressing CAR after being introduced into the subject. A method includes ex vivo transduction of peripheral blood T cells using a nucleic acid construct according to the present disclosure, and returning the transduced cells to the subject.

[0286] The present disclosure encompasses methods of preparing immune cells for use in immunotherapy, comprising introducing into such immune cells ex vivo a polynucleotide or vector encoding one of the CD94-specific chimeric antigen receptors disclosed herein.

[0287] The present disclosure also encompasses immune cells comprising a polynucleotide or lentiviral vector encoding one of the CD94-specific chimeric antigen receptors disclosed herein. In some aspects, these immune cells are used for immunotherapy (e.g., treating cancer).

[0288] The present disclosure also encompasses methods of genetically modifying immune cells to make them more suitable for allogeneic transplantation. According to a first aspect, immune cells can be made allogeneic, for example, by inactivating at least one gene expressing one or more T cell receptor (TCR) components, as disclosed in WO 2013 / 176915, which can be combined with inactivating genes encoding or regulating HLA or β2m protein expression. Thus, the risk of graft-versus-host syndrome and transplant rejection is significantly reduced.

[0289] In some aspects, provided herein are immune cells comprising chimeric antigen receptors of the present disclosure. In some aspects, the immune cells are immune effector cells. In some aspects, the immune cells are T cells. In some aspects, the immune cells are T lymphocytes selected from inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes, or helper T lymphocytes. In some cases, the immune cells are CD8+ cytotoxic T lymphocytes.

[0290] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising a scFv domain capable of binding to CD94; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain. In some aspects, the VH comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 20, and a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 21. In some aspects, the VL comprises: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6 or SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO: 24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the scFv domain comprises a VH and a VL.

[0291] In some aspects, VH comprises: CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 3, CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 4, and CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 5. In some aspects, VL comprises: CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 6, CDR L2 comprising the amino acid sequence YTS, and CDR L3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0292] In some aspects, the VH comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO: 19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO: 20, and a CDR H3 comprising the amino acid sequence shown in SEQ ID NO: 21. In some aspects, the VL comprises: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence shown in SEQ ID NO: 23, and a CDRL3 comprising the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the VL comprises: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO: 22, a CDR L2 comprising the amino acid sequence shown in SEQ ID NO: 24, and a CDRL3 comprising the amino acid sequence shown in SEQ ID NO: 8.

[0293] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:9.

[0294] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:9.

[0295] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:56.

[0296] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:56.

[0297] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:57.

[0298] In some aspects, the engineered human T cells comprise a chimeric antigen receptor comprising an amino acid sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO:57.

[0299] Whether before or after genetic modification of engineered cells (e.g., T cells), even if the genetically modified immune cells of the present disclosure are activated and proliferated independently of the antigen binding mechanism, the immune cells of the present disclosure, especially T cells, can be further activated and expanded using methods disclosed, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. T cells can be expanded in vitro or in vivo.

[0300] In some aspects, the T cells of the present disclosure are expanded by contacting with agents that stimulate the CD3 TCR complex and co-stimulatory molecules on the surface of the T cells, thereby generating activation signals for the T cells. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristic acid 13-acetate (PMA) or mitogenic lectins such as phytohemagglutinin (PHA) can be used to generate activation signals for T cells.

[0301] As a non-limiting example, a T cell population can be stimulated in vitro, such as by contacting with an anti-CD3 antibody or its antigen binding fragment, or an anti-CD2 antibody fixed on the surface, or by contacting with a protein kinase C activator (e.g., bryostatin) together with a calcium ion carrier. For the costimulation of auxiliary molecules on the surface of T cells, a ligand in conjunction with auxiliary molecules is used. For example, a T cell population can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under conditions suitable for stimulating T cell proliferation. Conditions suitable for T cell culture include appropriate culture media (e.g., minimum essential culture media or RPMI culture media 1640 or X-vivo 5, (Lonza)), which may contain factors necessary for proliferation and survival, including serum (e.g., fetal bovine serum or human serum), interleukin-2 (IL-2), insulin, IFN-g, IL-4, IL-7, GM-CSF, IL-10, IL-2, IL-15, TGFp and TNF-α or any other additive for cell growth known to those skilled in the art. Other additives that promote cell growth include, but are not limited to, surfactants, plasma products (plasmanate) and reducing agents, such as N-acetyl-cysteine ​​and 2-mercaptoethanol. Culture medium can include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1 and X-Vivo 20, Optimizer, to which amino acids, sodium pyruvate and vitamins are added, without serum or supplemented with an appropriate amount of serum (or plasma) or a group of determined hormones, and / or cytokines sufficient to support the growth and expansion of T cells. Antibiotics, such as penicillin and streptomycin, are only included in experimental cultures, not in cell cultures to be injected into subjects. Target cells are maintained under conditions necessary to support growth, such as appropriate temperature (e.g., 37°C) and atmosphere (e.g., air plus 5% O2). T cells exposed to different stimulation times can exhibit different characteristics.

[0302] In some aspects, the cells can be expanded by co-culturing with tissues or cells. The cells can also be expanded in vivo, for example, in the blood of a subject after the cells are administered to the subject.

[0303] IV. Antibody Production

[0304] Antibodies and antigen-binding fragments thereof that immunospecifically bind to CD94 (e.g., human CD94) can be produced by any method known in the art for synthesizing antibodies and antigen-binding fragments thereof, such as by chemical synthesis or by recombinant expression techniques. Unless otherwise indicated, the methods disclosed herein employ conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields of the art. Such techniques are disclosed, for example, in the references cited herein and are fully explained in the literature. See, e.g., Sambrook J et al., (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel FM et al., Current Protocols in Molecular Biology, John Wiley & Sons (1987 and annual updates); Current Protocols in Immunology, John Wiley & Sons (1987 and annual updates); Gait (ed.) (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein (ed.) (1991) Oligonucleotides and Analogues: A Practical Approach, IRL Press; Birren B et al., (eds.) (1999) Genome Analysis: A Laboratory Manual, Cold Spring Harbor Laboratory Press.

[0305] In some aspects, provided herein is a method for preparing an antibody or antigen-binding fragment that immunospecifically binds to CD94 (e.g., human CD94), comprising culturing a cell or host cell disclosed herein. In some aspects, provided herein is a method for preparing an antibody or antigen-binding fragment that immunospecifically binds to CD94 (e.g., human CD94), comprising expressing (e.g., recombinantly expressing) an antibody or antigen-binding fragment thereof using a cell or host cell disclosed herein (e.g., a cell or host cell comprising a polynucleotide encoding an antibody or antigen-binding fragment thereof disclosed herein). In some aspects, the cell is an isolated cell. In some aspects, an exogenous polynucleotide has been introduced into the cell. In some aspects, the method further comprises a step of purifying the antibody or antigen-binding fragment obtained from the cell or host cell.

[0306] Methods for producing polyclonal antibodies are known in the art (see, e.g., Chapter 11 in Short Protocols in Molecular Biology, (2002) 5th edition, Ausubel FM et al., eds., John Wiley and Sons, New York).

[0307] Monoclonal antibodies or their antigen-binding fragments can be prepared using a variety of techniques known in the art, including the use of hybridomas, recombinant and phage display techniques, yeast-based presentation techniques, or combinations thereof. For example, monoclonal antibodies or their antigen-binding fragments can be produced using hybridoma technology, including those known in the art and in, for example, Harlow E&Lane D, Antibodies:A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd edition 1988); Hammerling GJ et al., Monoclonal Antibodies and T-Cell Hybridomas 563 681 (Elsevier, NY, 1981) taught, or as disclosed in Kohler G&Milstein C (1975) Nature 256:495. Examples of yeast-based presentation methods that can be used to select and produce the antibodies disclosed herein include those disclosed in, for example, WO2009 / 036379A2; WO2010 / 105256; and WO2012 / 009568, each of which is herein incorporated by reference in its entirety.

[0308] In certain aspects, the hybridoma method first disclosed by Kohler et al., Nature, 256:495 (1975) can be used as described above to produce monoclonal antibodies or antigen-binding fragments thereof. In the hybridoma method, mice or other appropriate host animals are immunized as disclosed above to induce lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization, such as a mixture of variants of CD94. The lymphocytes are then fused with myeloma cells using a suitable fusing agent (such as polyethylene glycol) to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103, Academic Press, 1986).

[0309] In some aspects, the monoclonal antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment produced by a clonal cell (e.g., a hybridoma or host cell that produces a recombinant antibody or antigen-binding fragment), wherein the antibody or antigen-binding fragment immunospecifically binds to CD94 (e.g., human CD94), as determined by, for example, ELISA or other antigen-binding assays known in the art or in the Examples provided herein. In some aspects, the monoclonal antibody or antigen-binding fragment thereof can be a rodent or murine antibody or antigen-binding fragment thereof. In some aspects, the monoclonal antibody or antigen-binding fragment thereof can be a chimeric or humanized antibody or antigen-binding fragment thereof. In some aspects, the monoclonal antibody or antigen-binding fragment thereof can be a Fab fragment or a F(ab')2 fragment. The monoclonal antibodies or antigen-binding fragments thereof disclosed herein can be prepared, for example, by the hybridoma method disclosed in Kohler G & Milstein C (1975) Nature 256: 495, or can be isolated from a phage library, for example, using techniques as disclosed herein. Other methods for preparing clonal cell lines and monoclonal antibodies and antigen-binding fragments thereof expressed thereby are well known in the art (see, e.g., Chapter 11 in Short Protocols in Molecular Biology, (2002) 5th edition, Ausubel FM et al.).

[0310] The antigen-binding fragments of the antibodies disclosed herein can be generated by any technique known to those skilled in the art. For example, the Fab and F(ab')2 fragments disclosed herein can be generated by proteolytic cleavage of immunoglobulin molecules using enzymes such as papain (producing Fab fragments) or pepsin (producing F(ab')2 fragments). The Fab fragment corresponds to one of the two identical arms of a tetrameric antibody molecule and contains a complete light chain paired with the VH and CH1 domains of the heavy chain. The F(ab')2 fragment contains two antigen-binding arms of a tetrameric antibody molecule connected by a disulfide bond in the hinge region.

[0311] In addition, the antibodies or antigen-binding fragments thereof disclosed herein can also be produced using various phage display and / or yeast-based presentation methods known in the art. In phage display methods, proteins are displayed on the surface of phage particles carrying polynucleotide sequences encoding them. Specifically, the DNA sequences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or mouse cDNA libraries of affected tissues). The DNA encoding VH and VL domains is recombined with scFv linkers by PCR and cloned into a phagemid vector. The vector is electroporated in Escherichia coli and Escherichia coli is infected with helper phage. The phages used in these methods are generally filamentous phages, including fd and M13, and the VH and VL domains are generally recombinantly fused with phage gene III or gene VIII. Phages expressing antibodies or antigen-binding fragments thereof that bind to specific antigens can be selected or identified with antigens, such as using labeled antigens or antigens bound or captured to solid surfaces or beads. Examples of phage display methods that can be used to prepare the antibodies or fragments disclosed herein include methods disclosed in the following literature: Brinkman U et al., (1995) J Immunol Methods 182:41-50; Ames RS et al., (1995) J Immunol Methods 184:177-186; Kettleborough CA et al., (1994) Eur J Immunol 24:952-958; Persic L et al., (1997) Gene 187:9-18; Burton DR & Barbas CF (1994) Advan Immunol 57:191-280; PCT Application No. PCT / GB91 / 001134; International Publication Nos. WO 90 / 02809, WO 91 / 10737, WO 92 / 01047, WO 92 / 18619, WO 93 / 11236, WO 95 / 15982, WO 95 / 20401 and WO 97 / 13844; and U.S. Patent Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743 and 5,969,108.

[0312] The antibody or antigen-binding fragment thereof may be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGl, IgG2, IgG3 and IgG4.

[0313] a. Polynucleotide

[0314] In some aspects, provided herein are polynucleotides comprising nucleotide sequences encoding antibodies or antigen-binding fragments thereof disclosed herein that immunospecifically bind to CD94 (e.g., human CD94) antigen, or domains thereof (e.g., variable light chain region and / or variable heavy chain region), and vectors, e.g., vectors comprising such polynucleotides for recombinant expression in host cells (e.g., E. coli and mammalian cells).

[0315] In some aspects, provided herein are polynucleotides comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) disclosed herein.

[0316] In some aspects, provided herein are polynucleotides comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof that immunospecifically binds to a CD94 polypeptide (e.g., human CD94) and comprises an amino acid sequence as disclosed herein.

[0317] In some aspects, the antibodies or antigen-binding fragments thereof provided herein bind to CD94 and comprise six CDRs (e.g., CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3). The CDRs can be determined by various algorithms in the art, such as IMGT (Table 6), abYsis (Table 7), and Kabat (Table 8).

[0318] For example, the International Immunogenetics Information System (http: / / www.imgt.org) Based on the IMGT numbering of all immunoglobulins and T-cell receptor V-REGIONs from all species ( the internationalImMunoGeneTics information Lefranc MP et al., (1991) Nucleic Acids Res. 27(1):209-12; Ruiz M et al., (2000) Nucleic Acids Res. 28(1): 219-21; Lefranc MP (2001) Nucleic Acids Res. 29(1): 207-9; Lefranc MP (2003) Nucleic Acids Res. 31(1):307-10; Lefranc MP et al., (2005) Dev. Comp. Immunol. 29(3): 185-203; Kaas Q et al., (2007) Briefings in Functional Genomics&Proteomics, 6(4): 253-64).

[0319] The abYsis algorithm compiles antibody protein sequences from EMBLIG, which contains antibody information extracted from the EMBL-ENA database, the Kabat collection, and the Protein Data Bank (Swindells MB et al. (2017) J Mol Biol. 2017 Feb 3; 429(3): 356-364).

[0320] The Kabat definition is based on sequence variability and is the most commonly used definition (Kabat EA et al., supra).

[0321] Table 6 - IMGT CDR nucleotide sequences

[0322]

[0323] Table 7-abYsis CDR nucleotide sequences

[0324]

[0325] Table 8 - Kabat CDR nucleotide sequences

[0326]

[0327] In some aspects, isolated polynucleotides are disclosed herein comprising nucleic acid molecules encoding any VH or heavy chain of the anti-CD94 antibodies or antigen-binding fragments thereof disclosed herein. In some aspects, the VH is encoded by a polynucleotide sequence comprising a sequence corresponding to the polynucleotide sequence of SEQ ID NO: 10.

[0328] In some aspects, isolated polynucleotides are disclosed herein, comprising nucleic acid molecules encoding any VL or light chain of an anti-CD94 antibody or antigen-binding fragment thereof disclosed herein. In some aspects, the VL is encoded by a polynucleotide sequence comprising a sequence corresponding to the polynucleotide sequence of SEQ ID NO: 11.

[0329] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that is capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the polynucleotide sequence shown in SEQ ID NO: 12 or SEQ ID NO: 25, a CDR H2 comprising the polynucleotide sequence shown in SEQ ID NO: 13 or SEQ ID NO: 26, a CDR H3 comprising the polynucleotide sequence shown in SEQ ID NO: 14 or SEQ ID NO: 27, a CDR L1 comprising the polynucleotide sequence shown in SEQ ID NO: 15 or SEQ ID NO: 28, a CDR L2 comprising the polynucleotide sequence TACACCAGC or the polynucleotide sequence shown in SEQ ID NO: 29 or SEQ ID NO: 30, and a CDR L3 comprising the polynucleotide sequence shown in SEQ ID NO: 17.

[0330] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that is capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the polynucleotide sequence shown in SEQ ID NO: 12, a CDR H2 comprising the polynucleotide sequence shown in SEQ ID NO: 13, a CDR H3 comprising the polynucleotide sequence shown in SEQ ID NO: 14, a CDR L1 comprising the polynucleotide sequence shown in SEQ ID NO: 15, a CDR L2 comprising the polynucleotide sequence TACACCAGC, and a CDR L3 comprising the polynucleotide sequence shown in SEQ ID NO: 17.

[0331] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that is capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the polynucleotide sequence shown in SEQ ID NO: 25, a CDR H2 comprising the polynucleotide sequence shown in SEQ ID NO: 26, a CDR H3 comprising the polynucleotide sequence shown in SEQ ID NO: 27, a CDR L1 comprising the polynucleotide sequence shown in SEQ ID NO: 28, a CDR L2 comprising the polynucleotide sequence shown in SEQ ID NO: 29, and a CDR L3 comprising the polynucleotide sequence shown in SEQ ID NO: 17.

[0332] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that is capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the polynucleotide sequence shown in SEQ ID NO: 25, a CDR H2 comprising the polynucleotide sequence shown in SEQ ID NO: 26, a CDR H3 comprising the polynucleotide sequence shown in SEQ ID NO: 27, a CDR L1 comprising the polynucleotide sequence shown in SEQ ID NO: 28, a CDR L2 comprising the polynucleotide sequence shown in SEQ ID NO: 30, and a CDR L3 comprising the polynucleotide sequence shown in SEQ ID NO: 17.

[0333] In some aspects, the antibody or antigen-binding fragment thereof capable of binding to CD94 comprises a heavy chain variable region (VH) and a light chain variable region (VL). In some aspects, VH comprises a polynucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 10. In some aspects, VL comprises a polynucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 11.

[0334] In some aspects, the antibody or antigen-binding fragment thereof capable of binding to CD94 comprises a heavy chain variable region (VH) and a light chain variable region (VL). In some aspects, VH comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to SEQ ID NO: 10. In some aspects, VL comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity to SEQ ID NO: 11.

[0335] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having at least 85% identity with the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having at least 95% identity with the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having at least 98% identity with the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having at least 99% identity with the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 10.

[0336] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having at least 85% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having at least 90% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having at least 98% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having at least 99% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 11.

[0337] In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 10. In some aspects, the antibody or antigen-binding fragment comprises a VH comprising a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 10.

[0338] In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 11. In some aspects, the antibody or antigen-binding fragment comprises a VL comprising a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 11.

[0339] In some aspects, disclosed herein are isolated polynucleotides, comprising nucleic acid molecules encoding any chimeric antigen receptor (CAR) disclosed herein. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity with the sequence of the polynucleotide sequence of SEQ ID NO:18. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the sequence of the polynucleotide sequence of SEQ ID NO:18. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO:18.

[0340] In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% sequence identity with a sequence corresponding to a polynucleotide sequence of SEQ ID NO: 58. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with a sequence corresponding to a polynucleotide sequence of SEQ ID NO: 58. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence corresponding to a polynucleotide sequence of SEQ ID NO: 58.

[0341] In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to a sequence corresponding to a polynucleotide sequence of SEQ ID NO: 59. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% sequence identity to a sequence corresponding to a polynucleotide sequence of SEQ ID NO: 59. In some aspects, the chimeric antigen receptor comprises a polynucleotide sequence corresponding to a polynucleotide sequence of SEQ ID NO: 59.

[0342] In some aspects, the chimeric antigen receptor comprises from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising a scFv domain capable of binding CD94; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain. In some aspects, the signal peptide comprises a CD8α signal peptide. In some aspects, the scFv comprises a linker. In some aspects, the hinge comprises a CD8α hinge domain. In some aspects, the transmembrane domain comprises a CD8α transmembrane domain. In some aspects, the co-stimulatory domain comprises a 4-1BB co-stimulatory domain. In some aspects, the signaling domain comprises a CD3ζ signaling domain.

[0343] In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 39.

[0344] In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least 85% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least 90% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least 98% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having at least 99% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 39.

[0345] In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 39. In some aspects, the CD8α signal peptide comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 39.

[0346] In some aspects, the scFv comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 40.

[0347] In some aspects, the scFv comprises a polynucleotide sequence that is at least 85% identical to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence that is at least 95% identical to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence that is at least 98% identical to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence that is at least 99% identical to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 40.

[0348] In some aspects, the scFv comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 40. In some aspects, the scFv comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 40.

[0349] In some aspects, the linker comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 41.

[0350] In some aspects, the linker comprises a polynucleotide sequence that has at least 85% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence that has at least 90% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence that has at least 95% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence that has at least 98% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence that has at least 99% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 41.

[0351] In some aspects, the linker comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 41. In some aspects, the linker comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 41.

[0352] In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 42. In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 42.

[0353] In some aspects, the CD8α hinge domain comprises a polynucleotide sequence having at least 85% identity to the polynucleotide sequence of SEQ ID NO: 42. In some aspects, the CD8α hinge domain comprises a polynucleotide sequence having at least 90% identity to the polynucleotide sequence of SEQ ID NO: 42. In some aspects, the CD8α hinge domain comprises a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 42. In some aspects, the CD8α hinge domain comprises a polynucleotide sequence having at least 98% identity to the polynucleotide sequence of SEQ ID NO: 42. In some aspects, the CD8α hinge domain comprises a polynucleotide sequence having at least 99% identity to the polynucleotide sequence of SEQ ID NO: 42. In some aspects, the CD8α hinge domain comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 42.

[0354] In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence SEQ ID NO: 42. In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence SEQ ID NO: 42. In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence SEQ ID NO: 42. In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence SEQ ID NO: 42. In some aspects, the CD8 alpha hinge domain comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence SEQ ID NO: 42.

[0355] In some aspects, the CD8 alpha transmembrane domain comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 43. In some aspects, the CD8 alpha transmembrane domain comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 43.

[0356] In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having at least 85% identity to the polynucleotide sequence of SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having at least 90% identity to the polynucleotide sequence of SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having at least 98% identity to the polynucleotide sequence of SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having at least 99% identity to the polynucleotide sequence of SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 43.

[0357] In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence SEQ ID NO: 43. In some aspects, the CD8α transmembrane domain comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence SEQ ID NO: 43.

[0358] In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 44.

[0359] In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least 85% identity to the polynucleotide sequence of SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least 90% identity to the polynucleotide sequence of SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least 98% identity to the polynucleotide sequence of SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence having at least 99% identity to the polynucleotide sequence of SEQ ID NO: 44. In some aspects, the 4-1BB co-stimulatory domain comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 44.

[0360] In some aspects, the 4-1BB costimulatory domain comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence SEQ ID NO: 44. In some aspects, the 4-1BB costimulatory domain comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence SEQ ID NO: 44. In some aspects, the 4-1BB costimulatory domain comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence SEQ ID NO: 44. In some aspects, the 4-1BB costimulatory domain comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence SEQ ID NO: 44. In some aspects, the 4-1BB costimulatory domain comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence SEQ ID NO: 44.

[0361] In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 45.

[0362] In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence that is at least 85% identical to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence that is at least 95% identical to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence that is at least 98% identical to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence that is at least 99% identical to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence corresponding to the polynucleotide sequence of SEQ ID NO: 45.

[0363] In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 85% identity to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 90% identity to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 95% identity to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 98% identity to the polynucleotide sequence of SEQ ID NO: 45. In some aspects, the CD3 zeta signaling domain comprises a polynucleotide sequence having about 99% identity to the polynucleotide sequence of SEQ ID NO: 45.

[0364] Nucleic acid encoding heavy chain variable domain or heavy chain and nucleic acid encoding light chain variable domain or light chain can be in the same polynucleotide or in different polynucleotides. Nucleic acid encoding heavy chain variable domain or heavy chain and nucleic acid encoding light chain variable domain or light chain can be in the same vector or in different vectors.

[0365] Also provided herein are polynucleotides encoding the anti-CD94 antibodies, or antigen-binding fragments thereof, or domains thereof disclosed herein, which are optimized, for example, by codon / RNA optimization, replacement with a heterologous signal sequence, and elimination of mRNA instability elements. Thus, methods of generating nucleic acids encoding an anti-CD94 antibody, or antigen-binding fragment thereof, or domains thereof (e.g., heavy chain, light chain, VH domain, or VL domain) optimized for recombinant expression by introducing codon changes (e.g., codon changes encoding the same amino acid due to the degeneracy of the genetic code) and / or eliminating inhibitory regions in mRNA can be performed accordingly by adapting the optimization methods disclosed in, for example, U.S. Pat. Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498.

[0366] Polynucleotides encoding antibodies or their antigen-binding fragments disclosed herein or their domains can be produced from nucleic acids from a suitable source (e.g., hybridoma) using methods well known in the art (e.g., PCR and other molecular cloning methods). For example, PCR amplification using synthetic primers that can hybridize to the 3' and 5' ends of a known sequence can be performed using genomic DNA obtained from hybridoma cells that produce the antibody of interest. Such PCR amplification methods can be used to obtain nucleic acids comprising sequences encoding light chains and / or heavy chains of antibodies or their antigen-binding fragments. Such PCR amplification methods can be used to obtain nucleic acids comprising sequences encoding variable light chain regions and / or variable heavy chain regions of antibodies or their antigen-binding fragments. The amplified nucleic acids can be cloned into vectors for expression and further cloning in host cells, for example, to produce chimeric and humanized antibodies or their antigen-binding fragments.

[0367] The polynucleotides provided herein can be in the form of, for example, RNA or DNA. DNA includes cDNA, genomic DNA, and synthetic DNA, and the DNA can be double-stranded or single-stranded. If it is single-stranded, the DNA can be a coding strand or a non-coding (antisense) strand. In some aspects, the polynucleotide is a cDNA or a DNA lacking one or more endogenous introns. In some aspects, the polynucleotide is a non-naturally occurring polynucleotide. In some aspects, the polynucleotide is recombinantly produced. In some aspects, the polynucleotide is isolated. In some aspects, the polynucleotide is substantially pure. In some aspects, the polynucleotide is purified from natural components.

[0368] b. Cells and vectors

[0369] In some aspects, provided herein are vectors (e.g., expression vectors) comprising polynucleotides comprising nucleotide sequences encoding anti-CD94 antibodies and antigen-binding fragments thereof or domains thereof for recombinant expression in host cells, preferably mammalian cells. Also provided herein are cells, such as host cells, comprising such vectors for recombinant expression of anti-CD94 antibodies or antigen-binding fragments thereof disclosed herein. In some aspects, provided herein are methods for producing antibodies or antigen-binding fragments thereof disclosed herein, comprising expressing such antibodies or antigen-binding fragments thereof in host cells.

[0370] In some aspects, the recombinant expression of an antibody or antigen-binding fragment thereof or a domain thereof (e.g., a heavy chain or light chain disclosed herein) that specifically binds to CD94 (e.g., human CD94) disclosed herein comprises constructing an expression vector containing a polynucleotide encoding the antibody or antigen-binding fragment thereof or a domain thereof. Once a polynucleotide encoding an antibody or antigen-binding fragment thereof or a domain thereof (e.g., a heavy chain or light chain variable domain) disclosed herein is obtained, a vector for producing the antibody or antigen-binding fragment thereof can be produced by recombinant DNA technology using techniques well known in the art. Therefore, disclosed herein is a method for preparing a protein by expressing a polynucleotide containing a nucleotide sequence encoding an antibody or antigen-binding fragment thereof or a domain thereof (e.g., a light chain or a heavy chain). Methods well known to those skilled in the art can be used to construct an expression vector containing an antibody or antigen-binding fragment thereof or a domain thereof (e.g., a light chain or a heavy chain) coding sequence and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA technology, synthetic techniques, and in vivo genetic recombination. Also provided is a replicable vector comprising a nucleotide sequence encoding an antibody or its Fab disclosed herein, a heavy chain or light chain, a heavy chain or light chain variable domain, or a heavy chain or light chain CDR, which is operably connected to a promoter. For example, such vectors may include a nucleotide sequence encoding a constant region of an antibody or its Fab (see, e.g., International Publication Nos. WO 86 / 05807 and WO 89 / 01036; and U.S. Patent No. 5,122,464), and the variable domains of an antibody or its Fab may be cloned into such vectors for expression of a complete heavy chain, a complete light chain, or a complete heavy chain and light chain.

[0371] The expression vector can be transferred into cells (e.g., host cells) by conventional techniques, and the resulting cells can then be cultured by conventional techniques to produce the antibodies or antigen-binding fragments thereof disclosed herein, such as antibodies or antigen-binding fragments thereof comprising any anti-CD94 antibody disclosed herein.

[0372] Disclosed herein, in some aspects, are isolated vectors comprising any of the polynucleotides disclosed herein.

[0373] In some aspects, provided herein are host cells comprising any of the polynucleotides disclosed herein.

[0374] In some aspects, the host cell is selected from the group consisting of CHO, HEK-293T, HeLa and BHK cells. In some aspects, the CHO cell is a CHO-K1SP cell.

[0375] In some aspects, disclosed herein is a method of producing an antibody or antigen-binding fragment thereof capable of binding to CD94, the method comprising: (a) culturing any host cell disclosed herein in cell culture under conditions that allow expression of the antibody or antigen-binding fragment thereof; and (b) recovering the antibody or antigen-binding fragment thereof from the cell culture. In some aspects, disclosed herein is an antibody or antigen-binding fragment thereof obtainable by any of the production methods disclosed herein.

[0376] In some aspects, for expressing double-chain antibodies or antigen-binding fragments thereof, vectors encoding heavy and light chains can be co-expressed separately in host cells to express complete immunoglobulins, as described in detail below. In some aspects, the host cell contains a vector comprising a polynucleotide encoding the heavy chain and light chain of an antibody disclosed herein or its domain. In some aspects, the host cell contains two different vectors, a first vector comprising a polynucleotide encoding the heavy chain or heavy chain variable region of an antibody or its antigen-binding fragment disclosed herein, and a second vector comprising a polynucleotide encoding the light chain or light chain variable region of an antibody disclosed herein or its domain. In some aspects, the first host cell comprises a first vector comprising a polynucleotide encoding the heavy chain or heavy chain variable region of an antibody or its antigen-binding fragment disclosed herein, and the second host cell comprises a second vector comprising a polynucleotide encoding the light chain or light chain variable region of an antibody or its antigen-binding fragment disclosed herein. In some aspects, the heavy chain / heavy chain variable region expressed by the first cell is associated with the light chain / light chain variable region of the second cell to form an anti-CD94 antibody or its antigen-binding fragment disclosed herein. In some aspects, provided herein is a population of host cells comprising such a first host cell and such a second host cell.

[0377] In some aspects, provided herein are vector populations comprising: a first vector comprising a polynucleotide encoding a light chain / light chain variable region of an anti-CD94 antibody or antigen-binding fragment thereof disclosed herein and a second vector comprising a polynucleotide encoding a heavy chain / heavy chain variable region of an anti-CD94 antibody or antigen-binding fragment thereof disclosed herein. Alternatively, a single vector encoding and capable of expressing both heavy and light chain polypeptides may be used.

[0378] A variety of host-expression vector systems can be utilized to express the antibodies and antigen-binding fragments thereof disclosed herein (see, e.g., U.S. Pat. No. 5,807,715). Such host-expression systems represent vehicles that can produce and subsequently purify the coding sequences of interest, and also represent cells that can in situ express the antibodies or antigen-binding fragments thereof disclosed herein when transformed or transfected with the appropriate nucleotide coding sequences. These include, but are not limited to, microorganisms such as bacteria (e.g., Escherichia coli and Bacillus subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Pichia pastoris) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems (e.g., green algae such as Chlamydomonas reinhardtii) infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS (e.g., COS1 or COS), CHO, BHK, MDCK, HEK 293, NSO, PER.C6, VERO, CRL7030, HsS78Bst, HeLa, and NIH) with recombinant expression constructs. 3T3, HEK-293T, HepG2, SP210, R1.1, BW, LM, BSC1, BSC40, YB / 20 and BMT10 cells), the construct contains a promoter derived from a mammalian cell genome (e.g., a metallothionein promoter) or a mammalian virus (e.g., adenovirus late promoter; vaccinia virus 7.5K promoter). In some aspects, the cells disclosed herein for expressing antibodies and antigen-binding fragments thereof are CHO cells, such as those from CHO GS System TM In some aspects, the cells used to express the antibodies disclosed herein are human cells, such as human cell lines. In some aspects, the mammalian expression vector is pOptiVEC TMOr pcDNA3.3. In some aspects, bacterial cells (such as Escherichia coli) or eukaryotic cells (e.g., mammalian cells) particularly for expressing complete recombinant antibody molecules are used to express recombinant antibody molecules. For example, mammalian cells such as Chinese hamster ovary (CHO) cells in conjunction with vectors (such as major intermediate early gene promoter elements from human cytomegalovirus) are effective expression systems for antibodies (Foecking MK & Hofstetter H (1986) Gene 45: 101-105; and Cockett MI et al., (1990) Biotechnology 8: 662-667). In some aspects, antibodies or their antigen-binding fragments disclosed herein are produced by CHO cells or NS0 cells.

[0379] In addition, a host cell strain may be selected that modulates the expression of the inserted sequence or modifies and processes the gene product in a desired specific manner. Such modification (e.g., glycosylation) and processing (e.g., cleavage) of the protein product may contribute to the function of the protein. To this end, eukaryotic host cells that have the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL703O, COS (e.g., COS1 or COS), PER.C6, VERO, HsS78Bst, HEK-293T, HepG2, SP210, R1.1, BW, LM, BSC1, BSC40, YB / 20, BMT10 and HsS78Bst cells. In some aspects, the anti-CD94 antibodies disclosed herein are produced in mammalian cells, such as CHO cells, e.g., CHO-K1 cells. In some aspects, the anti-CD94 antibodies disclosed herein are produced in mammalian cells, such as HEK-293 cells.

[0380] In some aspects, a signal peptide is used to construct a vector containing the VH and / or VL or heavy and / or light chains of an antibody or antigen-binding fragment thereof provided herein.

[0381] Once the antibodies or antigen-binding fragments thereof disclosed herein are produced by recombinant expression, they can be purified by any method known in the art for purifying immunoglobulin molecules, for example, by chromatography (e.g., ion exchange chromatography, affinity chromatography, particularly by affinity chromatography for specific antigens after protein A and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for purifying proteins. In addition, the antibodies or antigen-binding fragments thereof disclosed herein can be fused to heterologous polypeptide sequences disclosed herein or otherwise known in the art to facilitate purification.

[0382] In some aspects, the antibodies or antigen-binding fragments thereof disclosed herein are isolated or purified. Typically, the isolated antibodies or antigen-binding fragments thereof are those that are substantially free of other antibodies or antigen-binding fragments thereof that have different antigenic specificities than the isolated antibodies or antigen-binding fragments thereof. For example, in some aspects, the preparation of antibodies or antigen-binding fragments thereof disclosed herein is substantially free of cellular material and / or chemical precursors.

[0383] In some aspects, the nucleic acid encoding the antibody disclosed herein or its antigen-binding fragment or CAR disclosed herein is provided in a viral vector. In some aspects, the viral vector is a retrovirus, a slow virus or a foamy virus.

[0384] In some aspects, the viral vector containing the coding sequence of the antibody or antigen-binding fragment thereof disclosed herein or the CAR disclosed herein is a retroviral vector or a lentiviral vector. The term "retroviral vector" refers to a vector containing structural and functional genetic elements mainly derived from retroviruses. The term "lentiviral vector" refers to a vector containing structural and functional genetic elements other than LTRs mainly derived from lentiviruses.

[0385] The retroviral vector used herein can be derived from any known retrovirus (e.g., type c retrovirus, such as Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), foamy virus, Friend, murine stem cell virus (MSCV) and Rous sarcoma virus (RSV)). The "retrovirus" of the present disclosure also includes human T-cell leukemia virus, HTLV-1 and HTLV-2, and retroviruses of the lentivirus family, such as human immunodeficiency virus, HIV-1, HIV-2, simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV) and other classes of retroviruses.

[0386] As used herein, a lentiviral vector refers to a vector derived from a lentivirus, which is a class (or genus) of retroviruses that cause slowly developing diseases. The viruses included in this group include HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); visna-maedi; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). The preparation of recombinant lentiviruses can be achieved using methods according to Dull et al. and Zufferey et al. (Dull et al., J. Virol., 1998; 72: 8463-8471 and Zufferey et al., J. Virol. 1998; 72: 9873-9880).

[0387] Retroviral vectors (i.e., lentiviral and non-lentiviral) used in the present disclosure can be made using standard cloning techniques by combining the desired DNA sequences in the order and orientation disclosed herein (Current Protocols in Molecular Biology, Ausubel, FM et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals; Eglitis et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol 150:4104-4115; U.S. Patent Nos. 4,868,116; 4,980,286; PCT Application WO 89 / 07136; PCT Application WO 89 / 02468; PCT Application WO 89 / 05345; and PCT Application WO 92 / 07573).

[0388] Suitable sources for obtaining retroviral (i.e., lentiviral and non-lentiviral) sequences that form the vectors include, for example, genomic RNA and cDNA available from commercial sources including the American Type Culture Collection (ATCC), Rockville, Md. These sequences may also be chemically synthesized.

[0389] V. Pharmaceutical Compositions

[0390] Provided herein are compositions comprising an antibody or antigen-binding fragment thereof disclosed herein, a chimeric antigen receptor (CAR) disclosed herein, or an engineered T cell disclosed herein, in a physiologically acceptable carrier, excipient, or stabilizer with a desired purity (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). An acceptable carrier, excipient, or stabilizer is nontoxic to the recipient at the dose and concentration employed.

[0391] In various aspects, the composition comprising an anti-CD94 antibody or antigen-binding fragment thereof, an anti-CD94 chimeric antigen receptor, or an engineered T cell targeting CD94 is provided in the form of a composition with a pharmaceutically acceptable carrier (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th Edition (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd Edition, Pharmaceutical Press (2000)).

[0392] In one aspect, the pharmaceutical compositions disclosed herein are used as medicaments. In one aspect, the pharmaceutical compositions disclosed herein are used as diagnostic agents, for example, to detect the presence of CD94 in a sample obtained from a patient (eg, a human patient).

[0393] Compositions to be used for in vivo administration may be sterile. This is easily achieved, for example, by filtration through sterile filtration membranes.

[0394] In some aspects, a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an anti-CD94 antibody or antigen-binding fragment thereof disclosed herein, a chimeric antigen receptor disclosed herein, or an engineered T cell disclosed herein and a pharmaceutically acceptable carrier.

[0395] In some aspects, disclosed herein are pharmaceutical compositions comprising any of the antibodies or antigen-binding fragments thereof disclosed herein.

[0396] In some aspects, disclosed herein are pharmaceutical compositions comprising any of the chimeric antigen receptors disclosed herein.

[0397] In some aspects, disclosed herein are pharmaceutical compositions comprising any engineered T cells disclosed herein. In some aspects, the engineered T cells are CAR-T cells.

[0398] Disclosed herein, in some aspects, are pharmaceutical compositions comprising any of the vectors disclosed herein.

[0399] In some aspects, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0400] VI. How to use

[0401] In some aspects, provided herein are methods of treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of any anti-CD94 antibody or antigen binding portion thereof, chimeric antigen receptor (CAR), engineered T cells, or a composition comprising the above substances as provided herein.

[0402] In some aspects, provided herein are methods of treating cancer in an individual, the methods comprising administering to the individual a therapeutically effective amount of any of the antibodies or antigen-binding fragments thereof disclosed herein.

[0403] In some aspects, provided herein is a method for treating cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of any engineered T cell disclosed herein. In some aspects, the method comprises administering to the individual a therapeutically effective amount of CAR natural killer cells, CAR macrophages, or CAR natural killer T cells. In some aspects, the method comprises administering to the individual a therapeutically effective amount of engineered immune cells. In some aspects, the engineered immune cells include any chimeric antigen receptor disclosed herein. In some aspects, the engineered immune cells are macrophages. In some aspects, the engineered immune cells are monocytes.

[0404] In some aspects, provided herein are methods of treating cancer in an individual, the methods comprising administering to the individual a therapeutically effective amount of any of the vectors disclosed herein.

[0405] In some aspects, provided herein are methods of treating cancer in an individual, the methods comprising administering to the individual a therapeutically effective amount of any of the pharmaceutical compositions provided herein.

[0406] In some aspects, the cancer is leukemia.

[0407] In some aspects, the leukemia is T-cell leukemia, T-cell large granular leukemia, natural killer cell large granular leukemia, or natural killer cell leukemia.

[0408] In some aspects, the cancer is lymphoma.

[0409] In some aspects, the lymphoma is T-cell lymphoma, extranodal natural killer / T-cell lymphoma, hepatosplenic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, or anaplastic large cell lymphoma.

[0410] In some aspects, the cancer is a CD94-expressing cancer.

[0411] In some aspects, the cancer is lung cancer, bladder cancer, or melanoma.

[0412] In some aspects, provided herein are methods of treating or preventing transplant rejection of a transplant in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the antibodies or antigen-binding fragments thereof disclosed herein.

[0413] In some aspects, provided herein are methods of treating or preventing transplant rejection of a transplant in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the chimeric antigen receptors provided herein.

[0414] In some aspects, provided herein are methods of treating or preventing transplant rejection of a transplant in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the engineered T cells disclosed herein.

[0415] In some aspects, provided herein are methods of treating or preventing rejection of a transplanted graft in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the vectors disclosed herein.

[0416] In some aspects, provided herein are methods of treating or preventing rejection of a transplanted graft in a patient, the methods comprising administering to the individual a therapeutically effective amount of any of the pharmaceutical compositions provided herein.

[0417] In some aspects, the transplant is an allogeneic transplant.

[0418] In some aspects, the transplant is an organ transplant.

[0419] In some aspects, the transplant is a hematopoietic cell transplant.

[0420] In some aspects, the transplant is induced pluripotent cell therapy.

[0421] In some aspects, provided herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any of the antibodies or antigen-binding fragments thereof disclosed herein.

[0422] In some aspects, provided herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any of the chimeric antigen receptors provided herein.

[0423] In some aspects, provided herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any of the engineered T cells disclosed herein.

[0424] In some aspects, provided herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any of the vectors disclosed herein.

[0425] In some aspects, provided herein are methods of modulating an immune response in a subject, the methods comprising administering to the individual a therapeutically effective amount of any of the pharmaceutical compositions provided herein.

[0426] In some aspects, the immune response is enhanced.

[0427] In some aspects, the immune response is mediated by natural killer cells and / or T cells. In some aspects, the antibodies or their antigen-binding fragments or compositions disclosed herein can be delivered to the subject by a variety of routes, such as parenteral, subcutaneous, intravenous, intradermal, transdermal, intrathecal and intranasal. In some aspects, the antibodies or their antigen-binding fragments or compositions are administered by intraperitoneal routes.

[0428] The amount of the antibody or antigen-binding fragment thereof or composition effective for treating or preventing a disorder depends on the nature of the disease. The precise dose employed in the composition also depends on the route of administration and the severity of the disease.

[0429] In some aspects, disclosed herein are methods of modulating an immune response in a subject, the method comprising administering to the individual a therapeutically effective amount of any antibody or antigen-binding fragment thereof described herein, any chimeric antigen receptor described herein, any engineered T cell described herein, or any pharmaceutical composition described herein.

[0430] In some aspects, the immune response is enhanced.

[0431] In some aspects, immune response is mediated by natural killer cells and / or T cells. In some aspects, the immune response of natural killer cells and / or T cells mediate autoimmune diseases. In some aspects, autoimmune diseases are systemic autoimmune diseases. In some aspects, systemic autoimmune diseases are systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis (RA), multiple sclerosis, type 1 diabetes (T1DM) or autoimmune liver disease (ALD).

[0432] The anti-CD94 antibodies or antigen-binding fragments thereof disclosed herein can be used to measure CD94 protein levels or CD94+ cells in biological samples using classical methods known to those skilled in the art, including immunoassays such as enzyme-linked immunosorbent assay (ELISA), fluorescence activated cell sorting (FACS), immunohistochemistry (IHC), immunoprecipitation, and Western blot. Suitable antibody assay labels are known in the art and include enzyme labels such as glucose oxidase; radioactive isotopes such as iodine ( 125 I. 121 I), carbon ( 14 C) Sulfur ( 35 S), tritium ( 3 H), Indium ( 121 In) and technetium ( 99 Tc); luminescent labels such as luminol; and fluorescent labels such as fluorescein and rhodamine, and biotin. Such labels can be used to label the antibodies or antigen-binding fragments thereof disclosed herein. Alternatively, a second antibody or antigen-binding fragment thereof that recognizes the anti-CD94 antibody or antigen-binding fragment thereof disclosed herein can be labeled and used in combination with the anti-CD94 antibody or antigen-binding fragment thereof to detect CD94 protein levels (e.g., soluble CD94 protein levels).

[0433] As used herein, the term "biological sample" refers to any biological sample obtained from a subject, cell line, tissue, or other cell source that may express CD94. Methods for obtaining tissue biopsies and body fluids from animals (e.g., humans) are well known in the art. The biological sample may also be a blood sample.

[0434] The anti-CD94 antibodies and antigen-binding fragments thereof disclosed herein may carry a detectable or functional label.

[0435] Examples of detectable moieties that can be used herein include, but are not limited to, radioisotopes, phosphorescent chemicals, chemiluminescent chemicals, fluorescent chemicals, enzymes, fluorescent polypeptides, and epitope tags. The detectable moiety can be a member of a binding pair that can be identified by its interaction with another member of the binding pair, and the label can be directly observed.

[0436] When fluorescent labels are used, specific binding members can be identified and quantified using existing microscopes and fluorescence activated cell sorting analysis (FACS) or a combination of both methods known in the art. The anti-CD94 antibodies or antigen-binding fragments thereof disclosed herein can carry fluorescent labels. Exemplary fluorescent labels include, for example, reactive and conjugated probes, such as aminocoumarins, fluorescein and Texas Red, Alexa Fluor dyes, Cy dyes, and DyLight dyes. The anti-CD94 antibodies can carry radioactive labels, such as isotopes. 3 H.14 C. 32 P. 35 S. 36 Cl, 51 Cr, 57 Co. 58 Co. 59 Fe, 67 Cu, 90 Y. 99 Tc, 111 In, 117 Lu, 121 I. 124 I. 125 I. 131 I. 198 Au, 211 At 213 Bi, 225 Ac and 186 Re. When a radioactive label is used, the specific binding of the anti-CD94 antibody or antigen-binding fragment to CD94 (e.g., human CD94) can be identified and quantified using currently available counting procedures known in the art. If the label is an enzyme, detection can be performed by any currently used colorimetric, spectrophotometric, fluorospectrophotometric, amperometric, or gasometric technique known in the art. This can be achieved by contacting the sample or control sample with the anti-CD94 antibody or antigen-binding fragment thereof under conditions that allow the formation of a complex between the antibody or antigen-binding fragment thereof and CD94. Any complex formed between the antibody or antigen-binding fragment thereof and CD94 in the sample and control is detected and compared.

[0437] In some aspects, provided herein is a method for detecting CD94 in a sample in vitro, comprising contacting the sample with an antibody or an antigen-binding fragment thereof, and optionally detecting binding of the antibody or an antigen-binding fragment thereof to CD94. In some aspects, provided herein is the use of an antibody or an antigen-binding fragment thereof provided herein for detecting CD94 in a sample in vitro. In one aspect, provided herein is an antibody or an antigen-binding fragment thereof or a pharmaceutical composition for detecting CD94 (e.g., soluble CD94) in a subject or in a sample obtained from a subject.

[0438] In some aspects, the subject is a mammal. In some aspects, the mammal is selected from the group consisting of humans, mice, hamsters, rabbits, non-human primates, guinea pigs, rats, zebrafish, pigs, sheep, cats or dogs. In some aspects, the subject is a human.

[0439] VII.Medicine Box

[0440] Provided herein are kits comprising one or more antibodies or antigen-binding fragments thereof disclosed herein, or conjugates thereof (eg, detection conjugates).

[0441] In some aspects, the kits include one or more chimeric antigen receptors provided herein.

[0442] In some aspects, the kit comprises one or more of any of the engineered T cells disclosed herein.

[0443] In some aspects, the kit comprises one or more of any of the vectors disclosed herein.

[0444] In some aspects, a kit comprises one or more of any of the pharmaceutical compositions provided herein.

[0445] In some aspects, the kit further comprises instructions for use.

[0446] In some aspects, the kit is used to treat a subject in need thereof.

[0447] In some aspects, the kit will therefore include cells, proteins or nucleic acid constructs of the present invention or related reagents in a suitable container device. In some aspects, a device for collecting samples and / or measuring samples from an individual can be provided in the kit. In some aspects, the kit includes, for example, cells, buffers, cell culture media, carriers, primers, restriction enzymes, salts, etc.

[0448] The components of the kit may be packaged in aqueous media or in lyophilized form. The container means of the kit typically include at least one vial, test tube, flask, bottle, syringe or other container means, in which the components may be placed, and preferably appropriately aliquoted. When the kit contains more than one component, the kit typically also includes a second, third or other additional container, in which the additional components may be placed separately. However, the vials may contain a combination of various components. Such containers may include injection molded or blow molded plastic containers, in which the desired vials are stored.

[0449] When the components of the medicine box are provided with one and / or more liquid solutions, the liquid solution is an aqueous solution, particularly preferably a sterile aqueous solution. The composition can also be formulated into an injectable composition. In this case, the container device itself can be a syringe, a pipette and / or other similar devices, from which the preparation can be applied to the infected area of ​​the body, injected into an animal, and / or even applied to other components of the medicine box and / or mixed with other components of the medicine box. However, the components of the medicine box can be provided in the form of dry powder. When reagents and / or components are provided in dry powder form, the powder can be restored by adding a suitable solvent. It is envisioned that the solvent can also be provided in another container device.

[0450] Example

[0451] Example 1. Analysis of anti-CD94 monoclonal antibody specificity

[0452] Anti-CD94 monoclonal antibodies are designed to treat NK cell or T cell lymphoproliferative disorders.

[0453] First, CD94 transcript expression in normal tissues was assessed. The Human Total RNA Survey Panel contains RNA from 21 normal human tissues and was provided by Applied Biosystems, Foster City, CA. Approximately 10 μg of total RNA from each source was reverse transcribed into cDNA using the Superscript III kit (Invitrogen). Quantitative PCR was performed using CD94 and β-actin primers using the following conditions: TM / StepOnePlus TM On a real-time PCR system, 50°C for 2 min, 94°C for 10 min, then 94°C for 15 sec, and 60°C for 60 sec were performed for 40 cycles. The expression of CD94 mRNA relative to β-actin mRNA in each sample was calculated ( Figure 1A ).

[0454] High levels of CD94 mRNA were detected in lymphoid organs, lymph nodes, spleen and NK cells ( Figure 1A Lower levels of CD94 mRNA were detected in the lungs and small intestine, which are known to contain small amounts of lymphoid tissue.

[0455] CD94 mRNA expression in 79 normal human tissues and lymphoid tissue subtypes was analyzed by high-density oligonucleotide arrays using the publicly available gene expression profiling database BioGPS (http: / / biogps.org). The analysis determined that CD94 transcripts were highly expressed in peripheral blood NK cells, while low levels were observed in CD8 T cells. CD94 mRNA was not expressed in other normal tissues ( Figure 1B ).

[0456] Next, anti-human CD94 monoclonal antibody ("UT-CD94") was generated. Human CD94 was stably transfected into L cells (mouse fibroblast cell line), and L cells expressing CD94 were used to immunize BALB / c mice. Splenocytes were isolated from immunized mice and hybridized with mouse myeloma cells by hybridoma technology to obtain monoclonal antibodies targeting human CD94 ( Figure 2 ).

[0457] The specificity of the UT-CD94 monoclonal antibody was then tested by flow cytometry. The UT-CD94 monoclonal antibody is a fluorescent dye conjugated to AF647 and was used to stain NK cell lymphoma and leukemia cell lines and normal donor peripheral blood mononuclear cells (PBMCs). Antibodies against CD3, CD20, CD14, and CD56 were also used to stain the cells. The UT-CD94 monoclonal antibody specifically stained human CD94 expressing L cells and human peripheral blood NK cells ( Figure 3A ), but not parental L cells, human B cells, T cells, or monocytes ( Figure 3B UT-CD94 mAb also binds to NK lymphoma and leukemia cell lines (NK-92, NKL, KHYG-1), but not to B cell lymphoma cell lines (SP53, Daudi, and Jeko-1) ( Figure 3C ). Flow cytometry analysis showed that UT-CD94 monoclonal antibody was specific for cells expressing CD94.

[0458] Example 2. CD94-specific CAR-T cell cytotoxicity analysis

[0459] The VH and VL sequences of the UT-CD94 monoclonal antibody of Example 1 were used to generate an anti-CD94 chimeric antigen receptor (CAR). The VH and VL sequences of the UT-CD94 monoclonal antibody were converted into single-chain variable fragments (scFv), and anti-CD94 CAR ("UT-CD94-CAR") was generated using the CD8α hinge, CD8α transmembrane domain, 4-1BB signaling domain, and CD3ζ signaling domain. Figure 4A ). The entire CAR sequence is incorporated into a lentiviral vector (pLVMG). The CDRs of the CAR amino acid and nucleotide sequences are shown in Tables 1-3 (amino acid sequence) and 4-6 (nucleotide sequence) above.

[0460] Normal donor T cells were purified from buffy coats, activated with anti-CD3, anti-CD28, and anti-CD2 antibodies in the presence of IL-2 for 2-3 days, and then transduced with lentivirus containing UT-CD94-CAR. Transduction efficiency was assessed by staining with His-tagged CD94 extracellular domain protein (ACROBiosystems, USA) followed by flow cytometric analysis with anti-His AF647 conjugated antibody. Flow cytometric analysis of surface expression of UT-CD94-CAR using CD94 extracellular domain protein staining revealed high transduction efficiency after 72 hours ( Figure 4B ).

[0461] Next, the cytotoxicity of UT-CD94-CAR T cells against NK-92 (NK cell lymphoma cell line) and NKL (NK cell leukemia cell line) was analyzed. NK-92 and NKL were stained with CellTrace TM Far Red cell staining kit (Thermofisher) was used to mark the B cell lymphoma cell line SP53 (mantle cell lymphoma cell line) with CFSE (Thermofisher). NK-92, NKL and SP53 cell lines were then co-cultured with UT-CD94-CAR transduced T cells at a ratio of 1:1:1 effector: tumor 1: tumor 2 (E:T1:T2). On the 1st, 2nd, 3rd and 4th days after dead cell staining (Thermofisher), the percentage of dead cells was determined by flow cytometry. The cytotoxicity of UT-CD94-CAR T cells against L cells (mouse fibroblast cell line) and L cells expressing human CD94 was also analyzed. Untransduced T cells or tumors alone were used as negative controls.

[0462] UT-CD94-CAR T cells induced significant lysis of CD94-positive NK lymphoma and leukemia cell lines (NK-92 and NKL) and L cells transfected with human CD94, but did not induce lysis of CD94-negative B cell lymphoma cell line (SP-53) or parental L cells ( Figures 5A-5F ). No significant lysis was observed in untransduced T cells.

[0463] This example demonstrates that the UT-CD94-CAR T cells disclosed herein exhibit high specificity and high cytotoxic activity against cells expressing CD94.

[0464] Example 3. Chimeric anti-CD94 antibodies block HLA-E interactions

[0465] Chimeric anti-human CD94 antibodies ("cUT-CD94") were synthesized by using hybridoma technology to replace the mouse Fc with human IgG1 Fc in the murine UT-CD94 monoclonal antibody generated in Example 1. The murine and chimeric anti-human CD94 antibodies were then used in various in vitro assays.

[0466] Since CD94 can function as a stimulatory or inhibitory receptor when forming heterodimers with NKG2C or NKG2A, respectively, it was determined whether the cUT-CD94 antibody could block the interaction with its ligand HLA-E. The NK leukemia cell line KHYG-1 was incubated with different concentrations of cUT-CD94 antibody or isotype control antibody for 1 hour, and then the cells were stained with HLA-E tetramers and analyzed by flow cytometry. The results showed that the cUT-CD94 antibody blocked the interaction with HLA-E ( Figure 6 ).

[0467] Since the interaction of NKG2A / CD94 heterodimers with their ligand HLA-E can lead to inhibition of NK cell function; it was therefore determined whether blocking CD94 leads to enhanced NK cell activation. NK cells were isolated from normal donor peripheral blood mononuclear cells by magnetic cell separation and incubated with the HLA-E expressing SP-53 mantle cell lymphoma cell line at an effector: target (E: T) ratio of 2: 1 in duplicate wells in the presence or absence of UT-CD94 antibody (mCD94 Ab) and cUT-CD94 antibody (cCD94Ab) or commercial mouse anti-CD94 antibody (clone DX22 from Biolegend catalog number 305502) and their respective isotype controls (mouse IgG1 isotype control antibody from Biolegend catalog number 401402 and human IgG1 isotype control antibody from Biocell catalog number BE0297). All antibodies were used at a concentration of 10 g / mL. After overnight incubation, CD137 expression was assessed by flow cytometry ( Figure 7 ).

[0468] For CD107a expression analysis, NK cells were isolated from normal donor peripheral blood mononuclear cells by magnetic cell separation, activated overnight with IL-2 (1200 IU / mL), and incubated with the HLA-E expressing SP-53 mantle cell lymphoma cell line at an effector:target (E:T) ratio of 2:1 in duplicate wells in the presence or absence of UT-CD94 antibody (mCD94 Ab) and cUT-CD94 antibody (cCD94 Ab) or commercial murine anti-CD94 antibody (clone DX22 from Biolegend catalog number 305502) and their respective isotype controls (mouse IgG1 isotype control antibody from Biolegend catalog number 401402 and human IgG1 isotype control antibody from Biocell catalog number BE0297). All antibodies were used at a concentration of 10 μg / mL. CD107a expression was assessed by flow cytometry after 16 hours of incubation ( Figure 8 ).

[0469] It was observed that blocking CD94 with UT-CD94 and cUT-CD94 antibodies resulted in increased NK cell activation, as evidenced by CD137 expression ( Figure 7 ) and CD107a degranulation ( Figure 8 ) determined. Compared with the commercial mouse anti-CD94 antibody (clone DX22 from Biolegend), the expression of CD137 and CD107a was significantly increased with the cUT-CD94 antibody. Specifically, 44-49% of cells treated with the cUT-CD94 antibody were found to express CD137, which was significantly higher than the 22-23% of cells expressing CD137 after treatment with the UT-CD94 antibody (mCD94 Ab) or the commercial mouse anti-CD94 antibody (DX22 Ab). In addition, 33-34% of cells treated with the cUT-CD94 antibody were found to express CD107a, which was significantly higher than the 16% of cells expressing CD107a after treatment with the commercial mouse anti-CD94 antibody (DX22) and the 14-16% of cells expressing CD107a after treatment with the UT-CD94 antibody (mCD94 Ab) produced in Example 1. Taken together, these results indicate that the cUT-CD94 antibody generated herein is more effective in driving CD107a and CD137 expression than currently commercialized implementations, as demonstrated by the DX22 murine anti-CD94 antibody.

[0470] Example 4. Anti-CD94 Antibody Drug Conjugate (Prediction)

[0471] Anti-CD94 antibody drug conjugates (AdCs) were generated using the UT-CD94 antibody of Example 1 or the chimeric cUT-CD94 antibody of Example 3. The anti-CD94 antibody was conjugated to a cytotoxic compound via a linker known in the art, such as those disclosed in Kostoba et al., Pharmaceuticals, 2021; 14(5):442; Tong et al., Molecules, Sep 27, 2021; 26(19):5847; and Drago et al., Nat Rev Clin Oncol, Jun 2021; 18(6):327-344. doi:10.1038 / s41571-021-00470-8. Epub Feb 8, 2021. The cytotoxicity of anti-CD94 AdCs against NK cell lymphoma or leukemia lines NK-92 and NKL was analyzed. NK-92 and NKL were treated with CellTrace TMFar Red cell staining kit (Thermofisher) was used for labeling, while the B-cell lymphoma cell line SP53 (mantle cell lymphoma cell line) was stained with CFSE (Thermofisher). NK-92, NKL and SP53 cell lines were co-cultured with anti-CD94 AdC. The percentage of dead cells was determined by flow cytometry on days 1, 2, 3 and 4 after dead cell staining (Thermofisher). Tumor cells alone were used as negative controls.

[0472] Example 5. CD94 expression in normal and tumor tissues

[0473] CD94 transcript expression is restricted in normal tissues. Analysis of single-cell RNAseq (scRNASeq) data from the Human Protein Atlas project showed that CD94 mRNA transcripts were only present in infiltrating immune cells, with the highest expression in NK cells in 25 normal tissues including important organs such as heart, lung, liver, kidney and spleen. Importantly, CD94 transcripts were not detected in epithelial cells, endothelial cells, muscle, adipocytes, cardiomyocytes, hepatocytes, neurons, renal tubular cells, etc. ( Figures 9A-9F Analysis of 29 immune cell types from peripheral blood mononuclear cells (PBMCs) from normal donors showed that CD94 transcripts were predominantly present in NK cells, CD8+ terminal effector T cells, and gd T cells, and at lower levels in CD8+ effector T cells, but absent in dendritic cells, B cells, and monocytes ( Figure 9G ).

[0474] A tissue array containing 32 different organs from 3 different healthy donors was tested using a commercial anti-CD94 monoclonal antibody (clone EPR21003, Abcam) titrated at 1:400. Standard immunohistochemistry protocols were followed and signals were detected with a Leica refined polymer detection kit. Positive signals (brown) were detected in a scattered manner in reactive lymphocytes of different organs (lymph nodes, spleen, thymus, tonsils, breast, small intestine, colon, stomach, uterus, ovaries, larynx, and esophagus). No positive signals were shown in the brain, cerebellum, adrenal glands, liver, thyroid, lung, pancreas, bone marrow, trachea, testis, heart, skeletal muscle, skin, nerves, salivary glands, kidneys, pericardium, eyes, prostate, and cervix. Fig. 10A ). Tonsils from normal donors ( Fig. 10B ) and NK / T cell lymphoma tumor tissues from patients ( Fig. 10C ) was used as a positive control, and strong CD94 signals were detected in both tissue sections.

[0475] CD94 protein expression is restricted in normal tissues. Consistent with the scRNAseq data, immunohistochemical analysis of normal donor tissue arrays showed that CD94 protein was only expressed in reactive lymphocytes dispersed in different organs ( Fig. 10A As expected, in normal tonsils ( Fig. 10B ) and NK / T cell lymphoma tissue ( Fig. 10C ) Strong staining of CD94 was detected in the

[0476] Example 6. Binding of anti-CD94 antibodies in NK cell leukemia cell lines

[0477] To evaluate the specificity of CD94 monoclonal antibodies, CD94 was stably knocked out in two NK cell leukemia cell lines (KHYG-1 and NK92) using CRISPR-Cas9 technology. The binding specificity of anti-CD94 antibodies was evaluated by flow cytometry against wild-type KHYG-1 and NK92 cell lines and their isogenic cell lines with CD94 knockout (KO) ( Fig.11 ). The anti-CD94 mAb bound to wild-type KHYG-1 and NK92 but not to their isogenic cell lines in which CD94 knockout confirmed its specificity.

[0478] Example 7. In vitro cytotoxic activity of anti-CD94 targeting CAR

[0479] Three different CAR molecules were synthesized using VH and VL from anti-CD94 monoclonal antibody ( Fig. 12A ). The anti-CD94 scFv was linked to the hinge / transmembrane domain of CD8a and the co-stimulatory domain derived from CD28, 4-1BB or OX-40. The CD3z signaling domain is present in these three constructs. The anti-CD94 CAR molecule was lentivirally transduced into normal donor T cells, and CAR transduction efficiency was assessed by flow cytometry 72 hours after the cells were stained with recombinant human CD94 protein ( Fig. 12B All three constructs showed good transduction efficiency. Stable transduction of NK cell leukemia cell line (NKL- Fig. 12C 、KHYG-1- Fig.12D and NK92- Fig.12E). Tumor cells were then cultured at an effector:target ratio of 0.5:1 in the presence or absence of CD94-targeted CAR T cells or untransduced T cells. Tumor cell lysis or growth was monitored by continuous imaging using the Incucyte Live Cell Analysis System. Strong cytotoxic activity was observed against three different NK cell leukemia cell lines (NKL, KHYG-1, and NK92) with anti-CD94 CAR T cells containing CD28, 4-1BB, or OX-40 co-stimulatory domains at a very low effector:target ratio of 0.5:1 (P<0.05). Figures 12C-12E ). In contrast, no significant lysis was observed with untransduced T cells.

[0480] Example 8. In vivo cytotoxic activity of CAR-targeted anti-CD94

[0481] To evaluate the antitumor activity of CD94-targeted CAR T cells in vivo, a CD94-positive patient-derived hepatosplenic T-cell lymphoma xenograft model was established. Tumor cells (1×10 6 The cells were injected intravenously into NSG mice via the tail vein and the mice were killed on day 49 when they were moribund. Fig.13A Photos of the liver and spleen at autopsy are shown. Intravenous injection of these tumor cells into NSG mice resulted in extensive hepatosplenomegaly in the mice, and tumors grew mainly in the liver, spleen, and bone marrow, with less involvement of the peripheral blood, which is very similar to the clinical manifestations in humans. These mice died at about 50 days due to the gradual growth of the tumor (data not shown). Single cell suspensions from the liver, spleen, bone marrow, and blood obtained at autopsy were analyzed by flow cytometry using human CD3 (hCD3), human CD45 (hCD45), and human CD94 (hCD94) antibodies ( Fig. 13B ). As shown in the figure, CD94 expression between hCD3+hCD45+ cells and hCD3-hCD45- cells was compared. NSG mice without tumor injection were used as controls. Tumor cells (1.5×10 6 tumor cells / mouse) were injected intravenously into NSG mice (5 mice / group) via the tail vein, and 10×10 6Anti-CD94 targeted CAR+T cells or non-transduced T cells. The anti-tumor effect of CAR T cells was evaluated by monitoring the survival rate of mice. The log-rank test was used to evaluate the survival difference between the treatment groups. Treatment of NSG mice with CD94-targeted CAR T cells resulted in a significant prolongation of survival compared with untreated mice or mice treated with non-transduced T cells (P<0.05). The survival rate of mice treated with each of the three different CAR constructs with CD28, 4-1BB or OX-40 costimulatory domains was 100% at 56 days.

[0482] ***

[0483] Unless otherwise indicated, the practice of the present disclosure will employ conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skills of those skilled in the art. Such techniques are fully described in the literature.

[0484] All references cited above and all references cited herein are incorporated by reference in their entirety.

[0485] Any examples provided herein are provided by way of illustration and not by way of limitation.

Claims

1. An antibody or antigen-binding fragment thereof capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: a complementarity determining region (CDR) H1 comprising the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:22, a CDRL2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO:23 or SEQ ID NO:24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:

8.

2. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 1, and the VL comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:

2.

3. An antibody or antigen-binding fragment thereof capable of binding to CD94, wherein the antibody or antigen-binding fragment thereof comprises: i) CDR H1, CDR H2 and CDR H3 comprising the CDR H1, CDR H2 and CDR H3 amino acid sequences of SEQ ID NO: 1; and ii) CDR L1, CDR L2 and CDR L3 comprising the CDR L1, CDR L2 and CDR L3 amino acid sequences of SEQ ID NO:

2.

4. The antibody or antigen-binding fragment thereof of claim 3, wherein the CDR is a Kabat-defined CDR, a Chothia-defined CDR, an AbM-defined CDR, or an IMGT-defined CDR.

5. The antibody or antigen-binding fragment of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:

1.

6. The antibody or antigen-binding fragment of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

1.

7. The antibody or antigen-binding fragment thereof as claimed in any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

1.

8. The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:

1.

9. The antibody or antigen-binding fragment thereof as claimed in any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO:

1.

10. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:

2.

11. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

2.

12. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

2.

13. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:

2.

14. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO:

2.

15. The antibody or antigen-binding fragment thereof of any one of claims 1 to 14, wherein the antibody or antigen-binding fragment thereof is human, humanized or chimeric.

16. The antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody or antigen-binding fragment thereof is an IgG antibody. The antibody or antigen-binding fragment thereof according to claim 16 , wherein the IgG antibody is an IgG1 antibody or an IgG4 antibody.

18. The antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody is an antigen-binding fragment of an antibody.

19. The antigen-binding fragment of the antibody of claim 18, wherein the fragment is selected from the group consisting of Fab, F(ab')2, Fv, scFv, scFv-Fc, dsFv and a single domain molecule.

20. The antigen-binding fragment of the antibody of claim 19, wherein the fragment is a scFv.

21. The antigen-binding fragment of the antibody of claim 19, wherein the fragment is a Fab.

22. An antigen-binding fragment of the antibody of claim 18, wherein the fragment is an intrabody.

23. The antibody or antigen-binding fragment thereof of any one of claims 1-15 or 18-22, wherein the antigen-binding fragment lacks an Fc region.

24. The antibody or antigen-binding fragment thereof of any one of claims 1-15 or 18-23, comprising VH and VL on the same polypeptide chain.

25. The antibody or antigen-binding fragment thereof of claim 24, wherein the VH and VL are connected by a linker.

26. The antibody or antigen-binding fragment thereof of any one of claims 1-25, wherein the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.

27. The antibody or antigen-binding fragment thereof of any one of claims 1-26, wherein the antibody or antigen-binding fragment thereof is a bispecific antibody.

28. A chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand-binding domain comprising an antigen-binding domain capable of binding to CD94; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain, wherein the antigen-binding domain comprises: a CDR H1 comprising the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:21, a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:22, a CDR L2 comprising the amino acid sequence YTS, SEQ ID NO:23 or SEQ ID NO:24, and a CDR L3 comprising the amino acid sequence shown in SEQ ID NO:

8.

29. The chimeric antigen receptor of claim 28, comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:

2.

30. The chimeric antigen receptor of any one of claims 28 or 29, wherein the antigen binding domain is a scFv.

31. The chimeric antigen receptor of any one of claims 28-30, wherein the co-stimulatory domain is selected from the group consisting of a 4-1BB co-stimulatory domain, a CD28 co-stimulatory domain, or an OX40 co-stimulatory domain.

32. The chimeric antigen receptor of any one of claims 28-31, wherein the hinge, the transmembrane domain, or both are from a CD8 alpha polypeptide.

33. The chimeric antigen receptor of any one of claims 28-32, wherein the signaling domain comprises a CD3 zeta signaling domain.

34. An engineered human T cell comprising a chimeric antigen receptor, the chimeric antigen receptor comprising, from N-terminus to C-terminus: (a) an extracellular ligand-binding domain comprising a scFv domain capable of binding to CD94, wherein the scFv domain comprises VL and VH; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain, wherein the VH comprises: a CDRH1 comprising the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:19, a CDR H2 comprising the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:20, a CDR H3 comprising the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:21, and wherein the VL comprises: a CDR L1 comprising the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:22, a CDR L2 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO:23 or SEQ ID NO:24, and a CDR L4 comprising the amino acid sequence YTS or the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:

26. CDRL3 having the amino acid sequence shown in NO:

8.

35. The engineered human T cell of claim 34, comprising a chimeric antigen receptor comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NOs: 9, 56 or 57.

36. An isolated polynucleotide comprising a nucleic acid molecule encoding the VH or heavy chain of the antibody or antigen-binding fragment thereof of any one of claims 1-26.

37. The isolated polynucleotide of claim 36, further comprising a nucleic acid molecule encoding the VL or light chain of the antibody or antigen-binding fragment thereof of any one of claims 1-26.

38. An isolated polynucleotide comprising a nucleic acid molecule encoding the VL or light chain of the antibody or antigen-binding fragment thereof of any one of claims 1-26.

39. An isolated polynucleotide comprising a nucleic acid molecule encoding the chimeric antigen receptor of any one of claims 28-33.

40. An isolated vector comprising the polynucleotide of any one of claims 36-39. A host cell comprising the polynucleotide of any one of claims 33-39 and the vector of claim 40.

42. The host cell of claim 41 , selected from the group consisting of CHO, HEK-293T, HeLa and BHK cells, optionally wherein the CHO cell is a CHO-K1SP cell.

43. A method for producing an antibody or antigen-binding fragment thereof capable of binding to CD94, the method comprising: (a) cultivating the cell of claim 41 or 42 in cell culture under conditions that allow expression of the antibody or antigen-binding fragment thereof; as well as (b) recovering the antibody or antigen-binding fragment thereof from the cell culture.

44. An antibody or an antigen-binding fragment thereof, which can be obtained by the method of claim 43.

45. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-26 or 44, the chimeric antigen receptor of any one of claims 28-33, the engineered T cell of any one of claims 34-35, or the vector of claim 40 and a pharmaceutically acceptable excipient.

46. ​​A method of treating cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-26 or 44, the chimeric antigen receptor of any one of claims 28-33, the engineered T cell of any one of claims 34-35, or the pharmaceutical composition of claim 45.

47. The method of claim 46, wherein the cancer is leukemia.

48. The method of claim 47, wherein the leukemia is T-cell leukemia, T-cell large granular leukemia, natural killer cell large granular leukemia, or natural killer cell leukemia.

49. The method of claim 46, wherein the cancer is lymphoma.

50. The method of claim 49, wherein the lymphoma is T-cell lymphoma, extranodal natural killer / T-cell lymphoma, hepatosplenic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, or anaplastic large cell lymphoma.

51. The method of claim 46, wherein the cancer is a CD94-expressing cancer.

52. A method for treating or preventing transplant rejection in a patient, the method comprising administering to the individual a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-26 or 44, the chimeric antigen receptor of any one of claims 28-33, the engineered T cell of any one of claims 34-35, or the pharmaceutical composition of claim 45.

53. The method of claim 52, wherein the transplant is an allogeneic transplant.

54. The method of claim 52, wherein the transplant is an organ transplant.

55. The method of claim 52, wherein the transplant is a hematopoietic cell transplant.

56. The method of claim 52, wherein the transplantation is induced pluripotent cell therapy.

57. A method of modulating an immune response in a subject, the method comprising administering to the individual a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-26 or 44, the chimeric antigen receptor of any one of claims 28-33, the engineered T cell of any one of claims 34-35, or the pharmaceutical composition of claim 45.

58. The method of claim 57, wherein the immune response is enhanced.

59. The method of claim 57, wherein the immune response is mediated by natural killer cells and / or T cells.

60. The method of claim 59, wherein the natural killer cells and / or T cells mediate the immune response of an autoimmune disease.

61. The method of claim 60, wherein the autoimmune disease is a systemic autoimmune disease.

62. The method of claim 61, wherein the systemic autoimmune disease is systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis (RA), multiple sclerosis, type 1 diabetes mellitus (T1DM), or autoimmune liver disease (ALD).

63. A method of treating cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of immune cells engineered to express the chimeric antigen receptor of any one of claims 28-33.

64. The method of claim 63, wherein the immune cell is a natural killer cell, a natural killer T cell, a macrophage, or a monocyte.